<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_CELREP6470 xml ?><?FILEmain xml ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEgr7 jpg ?><?FILEfx1 jpg ?><?FILEmmc1 pdf ?><?FILEmmc2 xlsx ?><?FILEmmc3 xlsx ?><?FILEmmc4 pdf ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Rep</journal-id><journal-id journal-id-type="iso-abbrev">Cell Rep</journal-id><journal-title-group><journal-title>Cell Reports</journal-title></journal-title-group><issn pub-type="epub">2211-1247</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6616584</article-id><article-id pub-id-type="publisher-id">S2211-1247(19)30768-5</article-id><article-id pub-id-type="doi">10.1016/j.celrep.2019.06.010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bacci</surname><given-names>Marina</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lorito</surname><given-names>Nicla</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ippolito</surname><given-names>Luigi</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramazzotti</surname><given-names>Matteo</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Luti</surname><given-names>Simone</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Romagnoli</surname><given-names>Simone</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Parri</surname><given-names>Matteo</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bianchini</surname><given-names>Francesca</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Cappellesso</surname><given-names>Federica</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Virga</surname><given-names>Federico</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Qiong</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Sim&#x000f5;es</surname><given-names>Bruno M.</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Marangoni</surname><given-names>Elisabetta</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Lesley-Ann</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Comito</surname><given-names>Giuseppina</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferracin</surname><given-names>Manuela</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Giannoni</surname><given-names>Elisa</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mazzone</surname><given-names>Massimiliano</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Chiarugi</surname><given-names>Paola</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">8</xref></contrib><contrib contrib-type="author"><name><surname>Morandi</surname><given-names>Andrea</given-names></name><email>andrea.morandi@unifi.it</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">8</xref><xref rid="fn2" ref-type="fn">9</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence 50134, Italy</aff><aff id="aff2"><label>2</label>VIB Center for Cancer Biology, Department of Oncology, University of Leuven, Leuven 3000, Belgium</aff><aff id="aff3"><label>3</label>Molecular Biotechnology Center (MBC), Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin 10126, Italy</aff><aff id="aff4"><label>4</label>The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK</aff><aff id="aff5"><label>5</label>Breast Cancer Now Research Unit, Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4GJ, UK</aff><aff id="aff6"><label>6</label>Institut Curie, PSL Research University, Translational Research Department, Paris 75248, France</aff><aff id="aff7"><label>7</label>Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna 40126, Italy</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>andrea.morandi@unifi.it</email></corresp><fn id="fn1"><label>8</label><p id="ntpara0010">Senior author</p></fn><fn id="fn2"><label>9</label><p id="ntpara0015">Lead Contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>02</day><month>7</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>02</day><month>7</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>02</day><month>7</month><year>2019</year></pub-date><volume>28</volume><issue>1</issue><fpage>104</fpage><lpage>118.e8</lpage><history><date date-type="received"><day>7</day><month>12</month><year>2018</year></date><date date-type="rev-recd"><day>13</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>3</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s)</copyright-statement><copyright-year>2019</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>Endocrine therapy (ET) is the standard of care for estrogen receptor-positive (ER<sup>+</sup>) breast cancers. Despite its efficacy, &#x0223c;40% of women relapse with ET-resistant (ETR) disease. A global transcription analysis in ETR cells reveals a downregulation of the neutral and basic amino acid transporter SLC6A14 governed by enhanced miR-23b-3p expression, resulting in impaired amino acid metabolism. This altered amino acid metabolism in ETR cells is supported by the activation of autophagy and the enhanced import of acidic amino acids (aspartate and glutamate) mediated by the SLC1A2 transporter. The clinical significance of these findings is validated by multiple orthogonal approaches in a large cohort of ET-treated patients, in patient-derived xenografts, and in <italic>in&#x000a0;vivo</italic> experiments. Targeting these amino acid metabolic dependencies resensitizes ETR cells to therapy and impairs the aggressive features of ETR cells, offering predictive biomarkers and potential targetable pathways to be exploited to combat or delay ETR in ER<sup>+</sup> breast cancers.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">ETR cells show high miR-23b-3p that reduces SLC6A14 and amino acids upload</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">ETR cells promote autophagy and aspartate and glutamate import via SLC1A2</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Aspartate and glutamate fuel anabolic and catabolic pathways in ETR breast cancers</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Targeting amino acid metabolic reprogramming is effective in ETR cells</p></list-item></list></p></abstract><abstract abstract-type="teaser" id="abs0025"><p>Bacci et&#x000a0;al. find that endocrine-resistant ER<sup>+</sup> breast cancers are characterized by enhanced miR-23b-3p, autophagy activation, and import of aspartate and glutamate that fuel catabolic and anabolic pathways, which are essential for their aggressive features. The molecular players involved in this metabolic scenario are of clinical significance and have prognostic and predictive value.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>endocrine therapy</kwd><kwd>resistance</kwd><kwd>metabolic reprogramming</kwd><kwd>estrogen receptor</kwd><kwd>amino acid transporters</kwd><kwd>aspartate</kwd><kwd>glutamate</kwd><kwd>miRNA</kwd><kwd>SLCs</kwd></kwd-group></article-meta><notes><p id="misc0010">Published: July 2, 2019</p></notes></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">The majority of breast tumors are positive for estrogen receptor &#x003b1; (called hereafter ER) and/or progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2). Since these tumors are dependent on estrogen for growth and survival, inhibiting this dependency with endocrine therapies (ETs) is the standard of care for these patients. ET agents include selective ER modulators (e.g., tamoxifen) which compete with estrogen for ER binding; selective ER downregulators (e.g., fulvestrant) that bind to and destabilize ER, inducing its degradation; and aromatase inhibitors (AIs; e.g., letrozole, anastrozole) which block the conversion of androgens to estrogens lowering estrogen levels. Over 50% of the ET-treated patients show an initial clinical benefit, but &#x0223c;40% experience <italic>de novo</italic> or acquired ET resistance (ETR). Therefore, there remains an urgent need for more effective therapeutic strategies. We have previously demonstrated that microRNA (miRNA)-dependent regulation of the expression of key metabolic genes enhances glucose-dependent metabolic plasticity in ETR cells (<xref rid="bib3" ref-type="bibr">Bacci et&#x000a0;al., 2016</xref>) and that impairing this reprogramming resensitizes ETR cells to therapy (<xref rid="bib47" ref-type="bibr">Morandi and Indraccolo, 2017</xref>). Concomitantly, a number of metabolic stimuli (e.g., nutrients, hormones, cytokines) modulate the miRNA expression, thus establishing a functional association, which can be altered to perturb energy homeostasis, as in the case of many tumors (<xref rid="bib17" ref-type="bibr">Dumortier et&#x000a0;al., 2013</xref>).</p><p id="p0035">Here, we performed genome-wide expression profiling of ETR long-term estrogen-deprived (LTED) ER<sup>+</sup> breast cancer cells that reveals a deregulation of amino acid transporters. Notably, the mechanism that sustains amino acid metabolism in ETR is not exclusively associated with estrogen deprivation but concurs with fulvestrant and tamoxifen resistance, thus highlighting the potential metabolic vulnerabilities to be exploited for either targeting or prognostic purposes.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Genome Profiling Reveals a Deregulated miR-23b-3p/SLC6A14 Axis in ETR Cells with Prognostic Value in ER<sup>+</sup> Breast Cancer</title><p id="p0040">To address the interconnection between miRNAs and genes associated with estrogen deprivation, we analyzed the global gene and miRNA expression profile from 3 independent experiments. We used an isogenic model in which parental MCF7 cells in the presence of estrogen (E2) were used to model a patient at primary diagnosis, MCF7 in the absence of E2 to mimic response to an AI, and finally LTED MCF7 cells to model relapse on AIs. Statistical analysis (1-way ANOVA, Benjamini-Hochberg correction followed by Student-Newman-Keuls post hoc tests; false discovery rate [FDR] &#x0003c;0.05, fold-change &#x0003e;2 and &#x0003c;&#x02212;2) revealed 62 miRNAs and 3,568 mRNAs significantly deregulated in MCF7-LTED versus MCF7, with or without E2. Within the parental MCF7 cells, 603 genes and 14 miRNAs were found differently regulated upon E2 treatment (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). Supervised hierarchical cluster analysis shows comparable clustering of both miRNA and gene expression data, with a clear separation between MCF7-LTED samples and the parental MCF7 cells subdivided into E2-treated and short-term E2-deprived samples (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). Although E2 treatment had, as expected, a significant impact on gene expression (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>), we focused on the differences between LTED and parental MCF7 cells either in the presence or absence of E2 addition to&#x000a0;model a clinical scenario that is independent of circulating E2 levels or prior endocrine agent administration, such as that of a post-menopausal patient who relapses after AI treatment (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Global Gene Expression and miRNA Analysis Reveals a Deregulated miR-23b-3p/SLC6A14 Node in LTED Compared to Parental MCF7 Cells</p><p>(A) Supervised hierarchical clustering of RNA transcripts (left) and miRNAs (right) of 3 biological replicates of MCF7, MCF7 deprived from estrogen (E2) for 3&#x000a0;days, and LTED cells that were subjected to gene or miRNA expression profiling using an Agilent Technologies assay. Differentially expressed genes (n&#x000a0;= 3,568; ANOVA) and miRNAs (n&#x000a0;= 62; ANOVA) were used for heatmap generation. High and low expression is normalized to the average expression across all of the samples. On the left side, association of the genes in the heatmap with leading edge genes resulting from GSEA analysis on the specified gene sets is identified.</p><p>(B) Gene set enrichment analysis enrichment plot of amino acid transport dataset showing a negative association between the MSigDb M188 dataset and the LTED gene expression profile. NES, normalized enrichment score.</p><p>(C) Anti-correlation network of differentially expressed miRNAs and mRNAs. Edge color is proportional to the strength of the anti-correlation (white to red&#x000a0;= low to high). Node color is proportional to the LTED versus MCF7 log fold change (red, downregulated; green, upregulated). Solute carrier (SLC) genes are labeled in black; other miRNAs or mRNAs are labeled in gray. miR-23b and SLC6A14 nodes are highlighted as large circles.</p><p>(D and E) Kaplan-Meier analysis of overall survival of BRCA TCGA cohort of ER<sup>+</sup> patients divided into high and low expressing, as described in <xref rid="sec4.4" ref-type="sec">Method Details,</xref> for miR-23b-3p expression (D: TGCA, high expressing, n&#x000a0;= 68; low expressing, n&#x000a0;= 475) or SLC6A14 (E: TGCA, high expressing, n&#x000a0;= 257; low expressing, n&#x000a0;= 467).</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0045">Using gene set enrichment analysis (GSEA) (<xref rid="bib65" ref-type="bibr">Subramanian et&#x000a0;al., 2005</xref>) (<xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>), many of the differentially expressed gene sets in LTED versus MCF7 cells are related to metabolic pathways (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). In particular, the LTED profile is negatively correlated with the gene set associated with amino acid transporters and metabolism (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B). Since miRNAs exert their role by binding to the target mRNAs and impairing their translation, their expression profiles are expected to be inversely correlated. Therefore, we created a correlative network based on gene and miRNA expression profiles to identify potential deregulated miRNA-mRNA nodes (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). Since the identification of metabolic dependencies could be of therapeutic and predictive value in ER<sup>+</sup> breast cancer and GSEA analysis revealed deregulated amino acid transport associated with LTED, we focused our attention on a metabolic-related network involving the solute carrier (SLC) family 6 member 14 (SLC6A14), a sodium-chloride-dependent amino acid transporter for all of the amino acids, with the exception of glutamate and aspartate (<xref rid="bib2" ref-type="bibr">Babu et&#x000a0;al., 2015</xref>). The SLC family plays a significant role in mediating amino acid transport across the plasma membrane (<xref rid="bib28" ref-type="bibr">Hediger et&#x000a0;al., 2004</xref>). Among the miRNAs reported to correlate with <italic>SLC6A14</italic> (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>A) was miR-23b-3p, which, as expected, showed an inverse correlation (<xref rid="bib5" ref-type="bibr">Bisognin et&#x000a0;al., 2012</xref>). Furthermore, miR-23b-3p was significantly upregulated in LTED cells compared to the parental MCF7 cells, independently of E2 treatment (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). The clinical relevance of the deregulated miR-23b-3p/SLC6A14 node observed was validated in retrospective clinical data. High expression of miR-23b-3p correlates with reduced survival in ER<sup>+</sup> breast cancer patients (hazard ratio [HR]&#x000a0;= 2.64, log-rank p&#x000a0;= 0.0007, n&#x000a0;= 543; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). Conversely, high expression of <italic>SLC6A14</italic> identifies a subset of good-prognosis ER<sup>+</sup> breast cancer patients (HR&#x000a0;= 0.47, log-rank p&#x000a0;= 0.0012, n&#x000a0;= 724; <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E). Similar results were obtained in an independent cohort of ER<sup>+</sup> breast cancers (<xref rid="mmc1" ref-type="supplementary-material">Figures S1</xref>B and S1C). A correlation analysis between miR-23b-3p and SLC6A14 was performed on the TCGA patients&#x02019; dataset selected based on higher (upper quartile) and lower (lower quartile) expression levels of miR-23b-3p (n&#x000a0;= 104). The correlation is significant and negative, and, crucially, <italic>SLC6A14</italic> expression is completely lost in the high miR-23b-3p-expressing tumors (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>D).</p></sec><sec id="sec2.2"><title>miR-23b-3p and SLC6A14 Expression Is Deregulated in ETR Models</title><p id="p0050">To determine whether the deregulation of the miR-23b-3p/SLC6A14 expression axis was a prerequisite of cells that are resistant to E2 deprivation or more generally a feature of ETR cells, we evaluated their expression in the LTED cells and in the MCF7-TAMR and MCF7-FULVR cell lines that are MCF7 derivatives, mimicking the acquired resistance to tamoxifen and fulvestrant, respectively. qRT-PCR analysis revealed a significant increase in the expression of miR-23b-3p (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A) and the reduced expression of <italic>SLC6A14</italic> (<xref rid="fig2" ref-type="fig">Figures 2</xref>B&#x02013;2D) in all of the ETR lines when compared to their parental counterpart. The miR-23b-3p mimic construct transfected into parental cells (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>A) induced SLC6A14 downregulation (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E), whereas the miR-23b-3p inhibitor transfected into LTED cells (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>B) led to an SLC6A14 increase, thereby demonstrating the functional relation between miR-23b-3p and SLC6A14 (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E). Consistent with reduced <italic>SLC6A14</italic> expression, all of the ETR cells displayed a reduced uptake of exogenous <sup>14</sup>C-labeled amino acids when compared to the parental cell counterparts (<xref rid="fig2" ref-type="fig">Figures 2</xref>F&#x02013;2H). This impairment in amino acids uptake could be reversed by downregulating miR-23b-3p expression (<xref rid="fig2" ref-type="fig">Figures 2</xref>I and <xref rid="mmc1" ref-type="supplementary-material">S2</xref>B). However, despite the reduced amino acids uptake, no significant difference was observed in <italic>de novo</italic> protein synthesis (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>J), suggesting no major impact on protein availability to support ETR cell growth. Moreover, anti-miR-23b-3p treatment slightly but significantly impaired LTED and TAMR MCF7 cell survival (<xref rid="mmc1" ref-type="supplementary-material">Figures S2</xref>C and S2D).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>miR-23b-3p/SLC6A14 Axis Is Deregulated in Different ETR Cells</p><p>(A&#x02013;D) ETR-derived and parental MCF7 (A and B), HCC1428 (C), and ZR75.1 (D) cells were subjected to qRT-PCR analysis using the assays described in the figure. Relative expression is shown using the parental cells as comparator. Data represent means &#x000b1; SEMs. One-way ANOVA; Dunnett corrected; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001. Each dot represents a biological replicate.</p><p>(E) Total protein lysates from MCF7 and LTED cells transfected with the oligos as described in the figure for 72&#x000a0;h were subjected to western blot analysis, as indicated.</p><p>(F&#x02013;H) <sup>14</sup>C-amino acids mixture upload was measured in ETR-derived and parental MCF7 (F), HCC1428 (G), and ZR75.1 (H) cells. The relative upload capacity is shown using parental cells as comparator. Data represent means &#x000b1; SEMs. One-way ANOVA; Dunnett corrected; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001. Each dot represents a biological replicate.</p><p>(I) <sup>14</sup>C-amino acids mixture upload was measured in ETR-derived MCF7 cells transfected for 72&#x000a0;h with either anti-miR-CTR or anti-miR-23b-3p oligos. The relative upload capacity is shown using anti-miR-CTR transfected cells as comparator. Data represent means &#x000b1; SEMs. Student&#x02019;s t test; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001. Each dot represents a biological replicate.</p><p>(J) LTED derivatives and parental counterparts of MCF7 and ZR75.1 cells were subjected to protein synthesis assay, as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. No differences were observed between parental and LTED cells in the absence or presence of the protein synthesis inhibitor cycloheximide (CHX, 50&#x000a0;&#x003bc;g/mL for 30&#x000a0;min). Data represent means &#x000b1; SEMs. One-way ANOVA; Dunnett corrected; ns, not significant.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec2.3"><title>GATA2 Is Enhanced during ETR and Controls miR-23b-3p-Dependent Amino Acids Upload</title><p id="p0055">GATA2 is a transcription factor involved in embryonic development, self-renewal, and stemness found overexpressed and involved in cancer (<xref rid="bib56" ref-type="bibr">Rodriguez-Bravo et&#x000a0;al., 2017</xref>). GATA2 expression is negatively controlled by E2 (<xref rid="bib74" ref-type="bibr">Yang et&#x000a0;al., 2017</xref>), and miR-23b-3p is a putative target of GATA2 (JASPAR Predicted Transcription Factor Targets, <ext-link ext-link-type="uri" xlink:href="http://amp.pharm.mssm.edu/Harmonizome" id="intref0010">http://amp.pharm.mssm.edu/Harmonizome</ext-link>). GATA2 expression was significantly enhanced in ETR cells both at the protein and mRNA levels (<xref rid="fig3" ref-type="fig">Figures 3</xref>A and 3B). E2 deprivation induced enhanced GATA2 expression (<xref rid="fig3" ref-type="fig">Figures 3</xref>C and 3D) and the subsequent increase in miR-23b-3p expression (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>E) in the parental cells, thus reinforcing the functional link between E2 deprivation, GATA2, and miR-23b-3p that characterized E2-deprived and endocrine agent-treated cells. Silencing GATA2 in all of the high-expressing ETR cells (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>A) resulted in reduced miR-23b-3p expression (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>F), enhanced amino acids uptake (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G), and impaired cell survival (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>H). The clinical significance of GATA2 in ER<sup>+</sup> breast cancer was validated in a large retrospective breast cancer patient cohort in which GATA2 higher expression identifies a subset of ER<sup>+</sup> breast cancers characterized by poorer prognosis (HR&#x000a0;= 1.86, log-rank p&#x000a0;= 0.0008, n&#x000a0;= 548; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>I).<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>GATA2 Is Enhanced during ETR and Controls miR-23b-3p-Dependent Amino Acids Upload</p><p>(A) Total protein lysates from ETR-derived and parental MCF7 cells were analyzed by western blotting with the antibody indicated.</p><p>(B) ETR-derived and parental MCF7 cells were subjected to qRT-PCR for GATA2 analysis. Relative expression is shown using the parental cells as comparator. Data represent means &#x000b1; SEMs. One-way ANOVA; Dunnett corrected; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01. Each dot represents a biological replicate.</p><p>(C&#x02013;E) Parental MCF7 cells were 3-day E2 deprived and subjected to either qRT-PCR (C and E) or western blot (D) analyses, as indicated in the figure. Data represent means &#x000b1; SEMs. Student&#x02019;s t test; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(F&#x02013;H) ETR-MCF7 cell derivatives transfected with non-targeting small interfering RNA (siRNA) (siCTR) or siRNA targeting GATA2 (siGATA2) for 72&#x000a0;h were subjected to qRT-PCR analysis for miR-23b-3p expression (F), <sup>14</sup>C-amino acids upload capacity (G), or cell viability assay using crystal violet (H). siCTR transfected cells were used as comparator. Data represent means &#x000b1; SEMs. Student&#x02019;s t test; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(I) Kaplan-Meier analysis of overall survival of ER<sup>+</sup> breast cancer patients divided into high and low GATA2 expressing, as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. Hazard ratio (HR) and log-rank Mantel-Cox p&#x000a0;values are shown.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec2.4"><title>Enhanced Autophagic Flux Is Essential for ETR Cell Survival</title><p id="p0060">Despite the reduced amino acids uptake in ETR cells, we did not observe a significant reduction in cell growth, protein synthesis, or protein content between LTED and parental cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>J, <xref rid="mmc1" ref-type="supplementary-material">S4</xref>A, and S4B). Therefore, we hypothesized that LTED cells may compensate for decreased amino acids uptake by activating macro-autophagy, hereafter referred as autophagy. Autophagy allows a cell to recycle dispensable and/or dysfunctional components to fuel catabolic and anabolic processes, including protein synthesis (<xref rid="bib24" ref-type="bibr">Galluzzi et&#x000a0;al., 2015</xref>). Moreover, SLC6A14 downregulation has been reported to induce autophagy activation (<xref rid="bib12" ref-type="bibr">Coothankandaswamy et&#x000a0;al., 2016</xref>). Western blot analysis revealed that LTED cells have increased levels of the microtubule-associated protein 1A-1B-light chain 3 (LC3), an established marker of autophagy activation, which was further enhanced by chloroquine (CQ) administration (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). CQ is a lysosomotropic agent that prevents endosomal acidification, hence inhibiting lysosomal hydrolases and preventing autophagosomal fusion and degradation. Since autophagy is a dynamic process, acute CQ administration results in the accumulation of autophagosomes, and the observed LC3-II increase is thus directly correlated with the autophagic flux (<xref rid="bib75" ref-type="bibr">Yoshii and Mizushima, 2017</xref>). Additional regulators of autophagy induction include mammalian target of rapamycin (mTOR) inhibition and beclin-1 expression, which functions as the central scaffold protein for autophagosome formation. The 3 MCF7 ETR derivatives showed increased levels of beclin-1 and LC3-II expression (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B). The autophagy activation described is functionally linked to miR-23b-3p expression, since ectopic miR-23b-3p overexpression in parental MCF7 cells enhanced LC3-II (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C), whereas the miR-23b-3p inhibitor reduced that of LTED cells (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D). In addition, ETR cells showed an increased number of LC3 puncta in the presence of CQ, when compared to parental cells (<xref rid="fig4" ref-type="fig">Figures 4</xref>E and 4F). Comparable results were obtained in ETR models of ZR75.1 and HCC1428 cells when compared to their parental counterparts (<xref rid="fig4" ref-type="fig">Figures 4</xref>F, <xref rid="mmc1" ref-type="supplementary-material">S4</xref>C, and S4D). Based upon this observation, longer CQ treatment (120 h) or silencing ATG7, a key component in the autophagosome formation, selectively impaired cell survival in ETR cells (<xref rid="fig4" ref-type="fig">Figures 4</xref>G and <xref rid="mmc1" ref-type="supplementary-material">S4</xref>E&#x02013;S4H), but not in the parental cells, indicating that targeting autophagy may resensitize ETR cells to endocrine agents.<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>ETR Cells Rely on miR-23b-3p-Dependent Autophagy Activation for Cell Survival</p><p>(A) LTED and parental MCF7 cells were subjected to 25&#x000a0;&#x003bc;mol/L chloroquine (CQ) for 16 h. Total protein lysates were analyzed by western blotting with the antibody indicated.</p><p>(B) Total protein lysates from ETR and parental MCF7 cells were subjected to western blotting analysis with the antibodies indicated.</p><p>(C and D) Total protein lysates from MCF7 (C) and LTED (D) cells transfected with the oligos as described in the figure for 72&#x000a0;h were subjected to western blot analysis, as indicated.</p><p>(E and F) MCF7 ETR and parental (E) cells were treated with 25&#x000a0;&#x003bc;mol/L of CQ for 16&#x000a0;h and subjected to confocal analysis (E, green: LC3; blue: TO-PRO-3, nuclei). Comparable analysis was performed for HCC1428-LTED (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>C), ZR75.1-LTED (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>D), and parental counterparts, and LC3 puncta were quantified (F) as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. Representative images are shown; scale bar, 10&#x000a0;&#x003bc;m. Data represent means &#x000b1; SEMs. Two-way ANOVA; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(G) ETR-derived and MCF7 parental cells were grown either in the absence (vehicle) or presence of 50&#x000a0;&#x003bc;mol/L CQ treatment for 120&#x000a0;h before subjecting them to cell viability assay. Data are presented as fold change survival fraction of CQ-treated versus vehicle-treated cells. Representative images are shown. Data represent means &#x000b1; SEMs and were compared to parental cells using 1-way ANOVA; Dunnett corrected; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(H) LTED and MCF7 parental cells were subjected to qRT-PCR using the assay indicated. Data represent means &#x000b1; SEMs. Student&#x02019;s t test; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(I) Kaplan-Meier analysis of overall survival of BRCA The Cancer Genome Atlas (TCGA) cohort of ER<sup>+</sup> patients divided into high and low expressing, as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref> for TNFAIP3 expression (high expressing, n&#x000a0;= 231; low expressing, n&#x000a0;= 493). The HR and log-rank Mantel-Cox p value are shown.</p><p>(J) Total protein lysates from ETR and parental MCF7 cells were subjected to immunoprecipitation (IP) using an anti-beclin-1 antibody and then subjected to immunoblotting (IB), as reported in the figure (top). Total lysates were also subjected to western blot analysis, as indicated (bottom).</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0065">An additional indication that autophagy may play a key role in ETR comes from the report that miR-23b-3p acts as a regulator of beclin-1 (<xref rid="bib26" ref-type="bibr">Gozuacik et&#x000a0;al., 2017</xref>). Ubiquitination of beclin-1 on Lys63 (K63) promotes autophagy, and this K63 ubiquitination is controlled by the balanced action of the ubiquitinating enzyme tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) and the deubiquitinating enzyme TNFAIP3 (also known as A20) (<xref rid="bib61" ref-type="bibr">Shi and Kehrl, 2010</xref>). Our analysis revealed that <italic>TNFAIP3</italic> is a predicted target gene of miR-23b-3p (using miRGator3.0 [<xref rid="bib8" ref-type="bibr">Cho et&#x000a0;al., 2013</xref>], a positive score was found in TargetScan, miRNAorg, PITA, PicTar, and miRDB). This interaction has also been validated by cross-linking immunoprecipitation (<xref rid="bib33" ref-type="bibr">Kishore et&#x000a0;al., 2011</xref>). Gene expression data (0.48-fold compared to MCF7<sup>&#x02212;</sup>E2 and 0.29-fold compared to MCF7<sup>+</sup>E2) and qRT-PCR analysis demonstrated a reduction in the expression of <italic>TNFAIP3</italic> in the LTED cells (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>H). This reduced expression is of clinical significance as low <italic>TNFAIP3</italic> expression identifies a poor prognosis subset of patients in independent studies (HR&#x000a0;= 0.52, log-rank p&#x000a0;= 0.0066; <xref rid="fig4" ref-type="fig">Figures 4</xref>I and <xref rid="mmc1" ref-type="supplementary-material">S1</xref>E). In support of these data, immunoprecipitation and western blot demonstrated an increase in not only the beclin-1 levels in the 3 ETR lines (see also <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B) but also the level of K63-ubiquinated beclin-1, thus sustaining autophagy in the ETR cells (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>J).</p></sec><sec id="sec2.5"><title>Increased Levels of Intracellular Aspartate and Glutamate Sustain the Aggressive Phenotype of ETR Cells</title><p id="p0070">Despite the demonstration that ER<sup>+</sup> cells are dependent on the SLC6A14 transporter (<xref rid="bib2" ref-type="bibr">Babu et&#x000a0;al., 2015</xref>) and that all ETR cell lines show a substantial reduction in <italic>SLC6A14</italic> expression (<xref rid="fig2" ref-type="fig">Figures 2</xref>B&#x02013;2D), it was notable that ETR cells show only a modest reduction in amino acids uptake (<xref rid="fig2" ref-type="fig">Figures 2</xref>F&#x02013;2H) and no significant difference in <italic>de novo</italic> protein synthesis (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>J), suggesting no major impact on protein availability to support ETR cell growth (<xref rid="mmc1" ref-type="supplementary-material">Figures S4</xref>A and S4B). To determine whether the maintenance of <italic>de&#x000a0;novo</italic> protein synthesis was accompanied by an imbalance in the intracellular amino acid levels, we analyzed their relative intracellular concentration in the LTED and parental MCF7 cells. High-performance liquid chromatography (HPLC) analysis revealed a significant increase in the intracellular levels of aspartate and glutamate in MCF7-LTED cells compared to parental cells (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A), and, moreover, the levels of aspartate and glutamate were unaffected by acute CQ treatment (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>I). These analyses indicate that the increased levels of aspartate and glutamate in LTED cells were not dependent on the enhanced autophagic flux. By contrast, a general decrease in essential amino acid intracellular levels was induced by CQ (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>I). We therefore hypothesized that an acidic amino acid transporter may be expressed at higher levels in the LTED model to provide the increased levels of aspartate and glutamate. Gene expression analysis of LTED and parental cells revealed 57 significantly deregulated SLC genes (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B), 9 of which encode amino acid transporters. Of these, 8 were downregulated in the LTED compared to parental cells, including SLC6A14. The exception was SLC1A2, a sodium-dependent high-affinity glutamate/aspartate transporter (3.4-fold increased in LTED cells compared to MCF7<sup>&#x02212;</sup>E2 and 4.1-fold compared to MCF7<sup>+</sup>E2). Western blot and qRT-PCR analyses confirmed SLC1A2 increased expression in the LTED cells compared to their corresponding parental line (<xref rid="fig5" ref-type="fig">Figures 5</xref>B and 5C), an observation that is independent of E2 stimulation (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). SLC1A2 has a predicted GATA2 binding site at the promoter region (JASPAR Predicted Transcription Factor Targets, <ext-link ext-link-type="uri" xlink:href="http://amp.pharm.mssm.edu/Harmonizome" id="intref0015">http://amp.pharm.mssm.edu/Harmonizome</ext-link>), and GATA2 silencing reduced SLC1A2 expression levels (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>B). SLC1A2 silencing further reduced the amino acids uptake of ETR cells (<xref rid="fig5" ref-type="fig">Figures 5</xref>D and 5E), which was already diminished compared to parental cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>F&#x02013;2H). Furthermore, SLC1A2 silencing impaired the incorporation by MCF7-LTED cells of <sup>14</sup>C-glutamate (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F) and <sup>14</sup>C-aspartate (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>G), thus reducing ETR cell survival (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>H) and MCF7-LTED invasion (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>A), an aggressive feature of LTED cells. In addition, LTED colony formation ability was reduced by selective aspartate and glutamate deprivation (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>I), thus reinforcing the notion that the selective upload of aspartate and glutamate drives the more &#x0201c;aggressive phenotype&#x0201d; of LTED cells.<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Aspartate and Glutamate Intracellular Levels Sustain the Aggressive Phenotype of ETR Cells</p><p>(A) Intracellular amino acids were extracted from LTED and parental MCF7 cells. Amino acid derivatization was performed using 4-<italic>N,N</italic>-dimethylaminoazobenzene-4&#x02032;-sulfonyl chloride (DABS). DABS-amino acids were detected at visible light wavelengths using HPLC. A representative chromatogram is reported, and the quantification of aspartate (Asp) and glutamate (Glu) from 4 biological replicates is represented in a box and whiskers graph (mean, 25th percentile, and 75th percentile are shown;&#x000a0;+ indicates the median of the values). Student&#x02019;s t test; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(B) Gene expression analysis of the significantly deregulated SLC transporters in LTED cells when compared to parental cells. Of the 57 significantly deregulated SLC genes, 9 amino acid transporters are shown in red. Each dot represents the mean value of the fold change derived by the analysis of&#x000a0;3 biological replicates (see <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). Western blot analysis of total lysates from parental and LTED MCF7 cells for SLC1A2 is reported in the inset.</p><p>(C) LTED and parental MCF7, HCC1428, and ZR75.1 cells were subjected to qRT-PCR using the&#x000a0;assay indicated. Data represent means &#x000b1; SEMs, n&#x000a0;= 3. Student&#x02019;s t test; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(D&#x02013;G) MCF7 ETR derivatives (D), HCC1428-LTED (E), and MCF7-LTED (F and G) were silenced using&#x000a0;the non-targeting control (siCTR) or siRNAs targeting SLC1A2 (siSLC1A2) for 72 h. <sup>14</sup>C-amino acid (D&#x000a0;and&#x000a0;E), <sup>14</sup>C-glutamate (F), and <sup>14</sup>C-aspartate (G) uptake was measured, and the radioactive signal normalized on protein content is shown, using siCTR-treated cells as comparators. Data represent means &#x000b1; SEMs. One-way ANOVA; Dunnett corrected; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(H) Complementarily, cell viability was measured using crystal violet staining and reported as fold change using parental cells as comparator. Data&#x000a0;represent means &#x000b1; SEMs. Student&#x02019;s t test; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(I) ETR and parental cells were subjected to colony formation assay either in the presence of all of the amino acids (all) or in the absence of both aspartate and&#x000a0;glutamate (&#x02212;Asp, &#x02212;Glu), as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. Data represent means &#x000b1; SEMs of 3 biological replicates. Two-way ANOVA; Bonferroni corrected;&#x000a0;<sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05.</p></caption><graphic xlink:href="gr5"/></fig></p></sec><sec id="sec2.6"><title>Aspartate and Glutamate Confer Metabolic Plasticity to ETR Cells</title><p id="p0075">To identify the fate of the uploaded aspartate and glutamate, we&#x000a0;performed a radioactive tracing analysis. The enhanced incorporation of radioactive aspartate observed in ETR cells (<xref rid="fig6" ref-type="fig">Figures 6</xref>A and <xref rid="mmc1" ref-type="supplementary-material">S6</xref>A) was paralleled by the increased radioactive labeling of lipids (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B), proteins (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C), and DNA (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>D) in ETR cells (<xref rid="mmc1" ref-type="supplementary-material">Figures S6</xref>B&#x02013;S6D). Conversely, the enhanced incorporation of glutamate in ETR cells (<xref rid="fig6" ref-type="fig">Figures 6</xref>E and <xref rid="mmc1" ref-type="supplementary-material">S6</xref>E) was paralleled only by a significant increase in radioactive DNA labeling (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>H), although a tendency toward enhanced radioactive lipids and proteins was observed in ETR cells (<xref rid="fig6" ref-type="fig">Figures 6</xref>F, 6G, <xref rid="mmc1" ref-type="supplementary-material">S6</xref>F, and S6G). To quantify the contribution of aspartate and glutamate to the LTED metabolism, cells were cultured in medium containing uniformly (U) labeled <sup>13</sup>C-aspartate (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>I) or <sup>13</sup>C-glutamate (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>J), and the <sup>13</sup>C-labeling of the tricarboxylic acid (TCA) cycle intermediates, together with metabolites that could act as precursors of anaplerotic reactions (e.g., uridine-5&#x02032;-triphosphate [UTP] for DNA synthesis and glutamine for protein synthesis), were analyzed by liquid chromatography-mass spectrometry (LC-MS). When U-<sup>13</sup>C-aspartate was&#x000a0;used, significant increases in <sup>13</sup>C-labeled &#x003b1;-ketoglutarate (&#x003b1;-KG), succinate, malate, oxaloacetate, and citrate were observed in LTED cells when compared to the parental cell counterpart (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>I). This was paralleled by a significant labeling of UTP and glutamine, indicating that aspartate is a major source of carbons for the TCA cycle and this could fuel anabolic pathways. Isotopologues analysis revealed that the TCA cycle in LTED cells occurs predominantly via canonical cycle activity, since a considerable fraction of citrate was 4 atoms of <sup>13</sup>C, whereas the fraction of 5 atoms is limited, suggesting that reductive carboxylation of &#x003b1;-KG, although occurring in LTED cells, is not their main feature (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>I). Comparable results were obtained when U-<sup>13</sup>C-aspartate was used in combination with (unlabeled) <sup>12</sup>C-glutamate (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>I), suggesting that the ability of aspartate to fuel the TCA cycle and subsequent anabolic and catabolic pathways is independent of the presence of glutamate. When U-<sup>13</sup>C-glutamate was used, significant increases in <sup>13</sup>C-labeled &#x003b1;-KG, succinate, malate, oxaloacetate, and citrate were observed in LTED cells when compared to the parental cell counterpart (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>J). This was paralleled by a significant labeling of UTP and glutamine, indicating that glutamate is a source of carbons for the TCA cycle and that can fuel anabolic pathways (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>J). Similar to aspartate, comparable results were obtained when U-<sup>13</sup>C-glutamate was used in combination with <sup>12</sup>C-aspartate (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>J).<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Metabolic Plasticity of ETR Cells Is Sustained by Aspartate and Glutamate</p><p>(A&#x02013;D) LTED and MCF7 cells were subjected to <sup>14</sup>C radioactive aspartate uptake (A) or cultured for 24&#x000a0;h in a medium containing radioactive aspartate. Lipids, proteins, or DNA were extracted in parallel and radioactive signal measured to monitor the amount of aspartate that is incorporated into lipids (B), proteins (C), and DNA (D), as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. Each value was normalized on protein content.</p><p>(E&#x02013;H) LTED and MCF7 cells were subjected to <sup>14</sup>C radioactive glutamate uptake (E) or cultured for 24&#x000a0;h in a medium containing radioactive glutamate. Lipids, proteins, or DNA were extracted in parallel and the radioactive signal was measured to monitor the amount of glutamate that is incorporated into lipids (F), proteins (G), and DNA (H), as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. Each value was normalized on protein content. Data represent means &#x000b1; SEMs, n&#x000a0;= 3. Student&#x02019;s t test; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001; ns, not significant.</p><p>(I and J) Schematic overview of the metabolism of downstream <sup>13</sup>C-labeled aspartate and fluxes and relative incorporation of <sup>13</sup>C carbons derived from aspartate in the metabolites (I). Schematic overview of metabolism of downstream <sup>13</sup>C-labeled glutamate and fluxes and relative incorporation of <sup>13</sup>C carbons derived from glutamate in the metabolites (J). Two-way ANOVA, Sidak corrected; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001; ns, not significant.</p><p>(K and L) Parental and LTED MCF7 cells were subjected to Seahorse XFe96 Mito Stress Test analysis and oxygen consumption rate (OCR) was measured in real time in the presence or absence of the indicated amino acids. Basal (K) and maximal (L) respiration was calculated as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>, based on the OCR after the administration of the ATP synthase inhibitor oligomycin, the proton uncoupler carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP), and the respiratory complex I inhibitor rotenone, together with the respiratory complex III inhibitor antimycin A. Data represent means &#x000b1; SEMs. One-way ANOVA; Dunnett&#x02019;s corrected; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01.</p></caption><graphic xlink:href="gr6"/></fig></p><p id="p0080">As ETR cells have enhanced metabolic plasticity (<xref rid="bib47" ref-type="bibr">Morandi and Indraccolo, 2017</xref>), we next addressed whether their increased aspartate and glutamate uptake was used, not only for anabolism but also as a source of energy. As assessed using the Seahorse XFe Mito Stress Test (<xref rid="fig6" ref-type="fig">Figures 6</xref>K, 6L, <xref rid="mmc1" ref-type="supplementary-material">S6</xref>K, and S6L), there were no significant differences in basal and maximal respiration by monitoring the oxygen consumption rate (OCR) of parental MCF7 cells either in the presence or absence of single or both amino acids. By contrast, concomitant deprivation of aspartate and glutamate in ETR cells (<xref rid="fig6" ref-type="fig">Figures 6</xref>K, 6L, <xref rid="mmc1" ref-type="supplementary-material">S6</xref>K, and S6L) significantly impaired their basal and maximal respiration. However, the withdrawal of each single amino acid was not sufficient to affect the OCR levels of ETR cells, suggesting that ETR cells can replenish the TCA cycle and subsequent electron transport chain with either amino acid, when the other is absent. This is&#x000a0;in line with the results of the metabolomic analysis using U-<sup>13</sup>C-glutamate and U-<sup>13</sup>C-asparate (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>I and 6J).</p></sec><sec id="sec2.7"><title>Increased Aspartate and Glutamate Levels in Patient-Derived Xenografts (PDXs) Correlate with ETR, and Impairing Their Transport Reduces the Metastatic Potential of ETR Cells <italic>In&#x000a0;Vivo</italic></title><p id="p0085">To further corroborate the role of the amino acid transporters in our model, we monitored SLC6A14 and SLC1A2 in an established ER<sup>+</sup> breast cancer PDX model (HBCx34 TAMR), which has acquired resistance to tamoxifen treatment <italic>in&#x000a0;vivo</italic> (<xref rid="bib13" ref-type="bibr">Cottu et&#x000a0;al., 2014</xref>). qRT-PCR analysis revealed a significant reduction in <italic>SLC6A14</italic> expression and a concomitant increase in <italic>SLC1A2</italic> in the TAMR PDXs when compared to the parental PDXs (<xref rid="fig7" ref-type="fig">Figures 7</xref>A and <xref rid="mmc1" ref-type="supplementary-material">7B</xref>). This differential SLC expression was accompanied by enhanced intratumoral levels of glutamate and aspartate, assessed using gas chromatography-MS (GC-MS) analysis (<xref rid="fig7" ref-type="fig">Figures 7</xref>C and 7D). Since we and others have previously reported that ETR cells display enhanced invasive abilities <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> (<xref rid="bib3" ref-type="bibr">Bacci et&#x000a0;al., 2016</xref>, <xref rid="bib52" ref-type="bibr">Nguyen et&#x000a0;al., 2015</xref>, <xref rid="bib38" ref-type="bibr">Liu et&#x000a0;al., 2014</xref>), we assessed whether impairing amino acid metabolism and availability, by targeting SLC1A2 or miR-23b-3p, had an impact on the invasive phenotype of the ETR cell lines, as observed <italic>in&#x000a0;vitro</italic> (<xref rid="mmc1" ref-type="supplementary-material">Figures S5</xref>A and S5B). To directly assess the role of the &#x02212;3p isoform of the miR-23b, we could not stably express the pre-miR-23b construct, as this results in the downregulation of both the &#x02212;3p or &#x02212;5p isoforms. Therefore, we transfected cells with either a control non-targeting miRNA (anti-miR-CTR) or an anti-miR-23b-3p in a short-term <italic>in&#x000a0;vivo</italic> assay, which has been previously published to reflect the metastatic potential of breast cancer cells (<xref rid="bib49" ref-type="bibr">Murugaesu et&#x000a0;al., 2014</xref>). Since metastatic burden resulted from the ability of the cells to survive in the circulation and to colonize secondary sites, transfected cells were labeled with cell tracker dyes, mixed in a 1:1 ratio, and injected via the tail vein into SCID mice. Imaging the lungs 1&#x000a0;h post-injection confirmed that an equal number of cells had been inoculated. An examination of the lungs 5&#x000a0;h post-injection revealed that a reduced number of anti-miR-23b-3p-treated cells were retained in the lungs compared to the anti-miR-CTR transfected cells, indicating that miR-23b-3p expression is required for efficient survival in the circulation and retention in the lungs (<xref rid="fig7" ref-type="fig">Figures 7</xref>E and <xref rid="mmc1" ref-type="supplementary-material">S7</xref>A). Equivalent results were obtained in a dye swap experiment (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S7</xref>B). Crucially, comparable data were obtained by targeting SLC1A2 (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>F and <xref rid="mmc1" ref-type="supplementary-material">S7</xref>C), indicating that both miR-23b-3p and SLC1A2 are responsible for the increased invasive ability of the ETR cells and that their targeting could reduce the aggressiveness of ETR breast cancer.<fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>Increased Aspartate and Glutamate Levels in PDX Correlate with ETR, and Impairing Their Transport Reduces the Metastatic Potential of ETR Cells</p><p>(A&#x02013;D) ET (i.e., tamoxifen)-sensitive and tamoxifen-resistant PDX (HBCx34) were obtained from ER<sup>+</sup> breast cancer specimens previously characterized as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. Tumor tissues were excised, and total RNA was extracted and subjected to qRT-PCR using the assay to detect <italic>SLC6A14</italic> (A) and <italic>SLC1A2</italic> (B). Each dot represents an independent mouse. Alternatively, tumor tissues were extracted and subjected to GC-MS (as detailed in <xref rid="sec4.4" ref-type="sec">Method Details</xref>) to evaluate the intratumoral levels of glutamate (C) and aspartate (D). Data represent means &#x000b1; SEMs. Student&#x02019;s t test; <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(E and F) MCF7-LTED cells were transfected with either anti-miR-23b-3p or a non-targeting control (anti-miR-CTR, E). Cells were labeled with CellTracker dyes (green for anti-miR-CTR and red for anti-miR-23b-3p) before injecting a mixture of anti-miR-23b-3p and anti-miR-CTR transfected cells in a 1:1 ratio into the tail vein of SCID mice (n&#x000a0;= 4 per group), as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref>. Similarly, SLC1A2 silenced (red) and siCTR transfected cells (green) were injected (F). The lungs were recovered at the time indicated and imaged to analyze the number of fluorescent cells that colonize the lungs. Data shown are means for tumor cell coverage per field of view (FOV); n&#x000a0;= 4 mice per group per time point &#x000b1; SEMs. Representative images are shown; scale bar, 200&#x000a0;&#x003bc;m. <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(G and H) Kaplan-Meier analysis of relapse-free survival of a curated cohort of ER<sup>+</sup> patients treated with tamoxifen in the adjuvant setting and divided into high and low expressing as described in <xref rid="sec4.4" ref-type="sec">Method Details</xref> for TNFAIP3 (G) and SLC6A14 expression (H). HR and log-rank Mantel-Cox p values are shown.</p><p>(I) Correlation of SLC1A2 expression with response to AI in 52 paired ER<sup>+</sup> breast cancer samples pre- and post-2-week letrozole treatment (<xref rid="bib45" ref-type="bibr">Miller et&#x000a0;al., 2007</xref>). A significant decrease in SLC1A2 expression was observed in the responder group, but no difference was found in the non-responder group (Wilcoxon paired t&#x000a0;test). ns, not significant. Each dot represents the value derived by a patient&#x02019;s specimen. Red lines connect the mean values pre- and post-letrozole treatment.</p><p>(J) Correlation of the change in the <italic>SLC1A2</italic> and <italic>AURKA</italic> expression levels following adjuvant fulvestrant treatment (Geo: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE33658" id="interref460">GSE33658</ext-link>, n&#x000a0;= 11; Spearman correlation and p value are indicated in the figure).</p></caption><graphic xlink:href="gr7"/></fig></p><p id="p0090">Finally, we evaluated whether the molecular players differentially expressed in ETR cells versus the parental counterpart and involved in the described reprogramming could have prognostic and predictive value for ET-treated ER<sup>+</sup> breast cancers. We used a curated dataset that combined &#x0223c;800 ER<sup>+</sup> breast cancer patients (from independent retrospective studies) who had been treated with adjuvant tamoxifen. Relapse-free survival was used as a surrogate for therapy response. Kaplan-Meier analysis revealed that patients characterized by lower levels of <italic>TNFAIP3</italic> (HR&#x000a0;= 1.64, p&#x000a0;= 0.01, n&#x000a0;= 809; <xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>G) or <italic>SLC6A14</italic> (HR&#x000a0;= 1.69, p&#x000a0;= 0.0029, n&#x000a0;= 809; <xref rid="fig7" ref-type="fig">Figures 7</xref>G and 7H) showed poorer relapse-free survival when compared with higher-expressing tumors. Multivariate Cox regression analysis revealed that the prognostic value is independent of proliferation (<xref rid="mmc1" ref-type="supplementary-material">Table S3</xref>). The predictive value of SLC1A2 in response and resistance to ET was validated by <italic>in silico</italic> analysis, which was performed by retrieving publicly available gene expression data from the biopsies of 52 ER<sup>+</sup> breast cancer patients taken before and after 2&#x000a0;weeks of neoadjuvant letrozole treatment (<xref rid="bib45" ref-type="bibr">Miller et&#x000a0;al., 2007</xref>). The patients were divided into responders and non-responders, defined by a &#x0003e;50% and a &#x0003c;50% reduction, respectively, in tumor volume following a further 3&#x000a0;months of letrozole treatment. A pairwise comparison shows a significant decrease in <italic>SLC1A2</italic> expression after 2&#x000a0;weeks of letrozole treatment in the responder cohort but not in the non-responder cohort (p&#x000a0;= 0.0007; <xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>I). The relevance of the players involved in response to selective downregulators of ER was finally validated in a small cohort of ER<sup>+</sup> breast cancer patients who received adjuvant fulvestrant. Since the clinical outcome was not available, we used the changes in the proliferation-related gene <italic>AURKA</italic> as a surrogate for therapy response. The evaluation of proliferation using Ki67 staining has been shown to predict poor long-term disease outcome (<xref rid="bib20" ref-type="bibr">Forbes et&#x000a0;al., 2008</xref>). Changes in the expression levels of <italic>SLC1A2</italic> induced by fulvestrant treatment were positively correlated with those of <italic>AURKA</italic> (rs&#x000a0;= 0.62, p&#x000a0;= 0.05, n&#x000a0;= 11; <xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>J), suggesting that SLC1A2 expression levels are linked to fulvestrant-induced changes in proliferation (i.e., response to therapy).</p><p id="p0095">These data support a role for amino acid metabolic reprogramming in ETR breast cancers, and the predictive value of the molecular and metabolic players identified should be validated in clinical prospective (neoadjuvant) trials.</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0100">The data presented in this study highlight the amino acid metabolic pathway as an important determinant of resistance to ET in ER<sup>+</sup> breast cancers. In particular, molecular reprogramming occurs and sustains the catabolic and anabolic processes of ETR breast cancer cells by (1) activating autophagy and (2) modulating the expression of amino acid transporters to selectively import certain amino acids (in this case, aspartate and glutamate).</p><p id="p0105">This study originated from the analysis of extensively characterized ER<sup>+</sup> cells adapted to study ETR that we along with others have demonstrated to be clinically relevant (<xref rid="bib41" ref-type="bibr">Martin et&#x000a0;al., 2003</xref>, <xref rid="bib42" ref-type="bibr">Martin et&#x000a0;al., 2012</xref>, <xref rid="bib52" ref-type="bibr">Nguyen et&#x000a0;al., 2015</xref>, <xref rid="bib59" ref-type="bibr">Sanchez et&#x000a0;al., 2011</xref>, <xref rid="bib48" ref-type="bibr">Morandi et&#x000a0;al., 2013</xref>, <xref rid="bib21" ref-type="bibr">Fox et&#x000a0;al., 2013</xref>, <xref rid="bib54" ref-type="bibr">Plaza-Menacho et&#x000a0;al., 2010</xref>, <xref rid="bib38" ref-type="bibr">Liu et&#x000a0;al., 2014</xref>). In addition, <italic>in&#x000a0;vitro</italic> findings were validated using PDX, lung retention assay, and retrospective clinical data derived from ET-treated patients.</p><p id="p0110">miR-23b is a member of the miR-23b/-27b/-24-1 cluster, and its deregulation has been reported in several types of cancer, although no conclusive results to date have provided a link between its role as an oncomiR or as a tumor suppressor. miR-23b-enhanced expression levels were found in renal cell carcinomas (<xref rid="bib76" ref-type="bibr">Zaman et&#x000a0;al., 2012</xref>), lymphomas (<xref rid="bib36" ref-type="bibr">Li et&#x000a0;al., 2013</xref>), non-small-cell lung cancers (<xref rid="bib4" ref-type="bibr">Begum et&#x000a0;al., 2015</xref>), and pancreatic cancers (<xref rid="bib7" ref-type="bibr">Chen et&#x000a0;al., 2017</xref>). Conversely, reduced levels were found to be associated with colon cancer (<xref rid="bib78" ref-type="bibr">Zhang et&#x000a0;al., 2011</xref>) and multiple myeloma (<xref rid="bib22" ref-type="bibr">Fulciniti et&#x000a0;al., 2016</xref>). Reduced levels of miR-23b were found to promote the chemoresistance of gastric cancers (<xref rid="bib1" ref-type="bibr">An et&#x000a0;al., 2015</xref>) and radioresistance in pancreatic cancers (<xref rid="bib73" ref-type="bibr">Wang et&#x000a0;al., 2013</xref>). An additional layer of complexity may come from the &#x02212;5p and &#x02212;3p isoforms that could have independent and/or opposing effects in different tissue contexts. Since some of the above-mentioned studies did not dissect which of the isoforms were predominant in the cohort of tumors analyzed, some of the discrepancies observed may derive from such bias. In this study, enhanced miR-23b-3p expression characterizes ETR breast cancer cells and a subset of breast cancer patients who show a worse prognosis. Since stable knockdown of miR-23b-3p <italic>in&#x000a0;vivo</italic> could be achieved only by concomitant downmodulation of the &#x02212;5p, we have opted for a short-term assay (i.e., quantification of residing cells in the lung after tail vein injection). Lung retention assay has some limitations and does not recapitulate the complex mechanism of the full metastatic cascade. However, we have carefully selected the time point of the analysis such that the ability of a given cell to be retained is likely due to the ability to survive and to colonize the lung. The priming event that leads to miR-23b-3p-enhanced expression is the upregulation of the transcription factor GATA2 mediated by ER signaling disengagement. GATA2 has been reported to favor breast cancer progression (<xref rid="bib72" ref-type="bibr">Wang et&#x000a0;al., 2012</xref>) and to regulate chemotherapy resistance and tumorigenicity in prostate cancer (<xref rid="bib70" ref-type="bibr">Vidal et&#x000a0;al., 2015</xref>). Crucially, GATA2 silencing impairs the miR-23b-3p-dependent amino acid transport regulation and ETR cell survival and has a prognostic value in ER<sup>+</sup> breast cancer.</p><p id="p0115">miR-23b-3p-enhanced levels in ETR cells are paralleled by a significant decrease in its target SLC6A14, an amino acid transporter that has been demonstrated to be an ER-dependent gene, and its expression was associated exclusively with ER<sup>+</sup> breast cancers. Moreover, SLC6A14 targeting is sufficient to induce autophagy-dependent cell death in ER<sup>+</sup> breast cancer models (<xref rid="bib31" ref-type="bibr">Karunakaran et&#x000a0;al., 2011</xref>). Since the reduced expression levels of SLC6A14 are compatible with ER<sup>+</sup> ETR cell survival, it is plausible that SLC6A14 downregulation may have been caused by a miR-23b-3p-induced adaptation, thus establishing a metabolic phenotype of the ETR cells that is characterized by enhanced pro-survival autophagy and the reliance on another amino acid transporter to compensate for the reduction in amino acid import caused by SLC6A14 impairment. ETR cells and parental cells show comparable cell growth rates and protein synthesis, although the import of amino acids is reduced in ETR cells. We hypothesized that autophagy could compensate for the reduced amino acids import. However, amino acids uptake, although significantly reduced, was not abolished, suggesting that other amino acid transporters may still function in ETR cells. It has been reported that glutamine can contribute to ETR cell survival in an MYC-dependent mechanism (<xref rid="bib60" ref-type="bibr">Shajahan-Haq et&#x000a0;al., 2014</xref>) and that autophagy activation could support tamoxifen resistance (<xref rid="bib11" ref-type="bibr">Cook et&#x000a0;al., 2011</xref>). Moreover, tamoxifen resistance could be supported by importing leucine in an LLGL2-dependent fashion (<xref rid="bib58" ref-type="bibr">Saito et&#x000a0;al., 2019</xref>). Our data revealed that SLC1A2 expression and the subsequent increases in the intracellular levels of aspartate and glutamate and uptake in ETR cells and PDX models confer a catabolic and anabolic advantage to ETR breast cancers.</p><p id="p0120">Our analyses show that both autophagy and aspartate and glutamate uploaded together establish a metabolic condition that sustains resistance to ET. Although this phenomenon should warrant further investigation, a potential explanation of the need for both autophagy and selective amino acid import may come from the reduction in essential amino acid levels that we have observed following autophagy inhibition. In this context, the aspartate and glutamate that are not affected by autophagy inhibition could be used to derive all of the other non-essential amino acids. In addition, glutamate and aspartate import could mitigate the effects caused by a severe decrease in the intracellular levels of amino acids, an established activator of autophagy (<xref rid="bib23" ref-type="bibr">Galluzzi et&#x000a0;al., 2014</xref>), to modulate the flux. This promotes a pro-survival autophagy, without the activation of a pro-apoptotic autophagic flux, which has been reported after the acute targeting of SLC6A14. In addition, <italic>in silico</italic> analysis of the METABRIC database (<xref rid="bib53" ref-type="bibr">Pereira et&#x000a0;al., 2016</xref>) shows that SLC1A2 and SLC6A14 are not concomitantly overexpressed or amplified in breast cancers and may be mutually exclusive (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S7</xref>D). It is interesting to note that SLC1A2 expression has been reported to play a role in different cancers. SLC1A2 undergoes a genomic breakpoint in its 5&#x02032; region and forms a fusion gene with CD44 in gastric and colorectal cancers (<xref rid="bib69" ref-type="bibr">Tao et&#x000a0;al., 2011</xref>, <xref rid="bib62" ref-type="bibr">Shinmura et&#x000a0;al., 2015</xref>). The CD44-SLC1A2 aberration induces higher glutamate intracellular levels, and SLC1A2 targeting resensitizes tumors to chemotherapy (<xref rid="bib69" ref-type="bibr">Tao et&#x000a0;al., 2011</xref>). Similarly, the enhanced levels of SLC1A2 in the ETR breast cancer models resulted in a significant increase in intracellular and intratumoral aspartate and glutamate levels. Once targeted, ETR cellular aggressive features are reduced and cells are resensitized to ET. Although we did not investigate the potential fusion gene in the ETR models analyzed, gene expression profiling revealed that <italic>CD44</italic> expression is upregulated in LTED cells (7.3-fold when compared to parental MCF7), and therefore it would be interesting to investigate whether a CD44-SLC1A2 fusion may also occur in ETR breast cancer models. The role of aspartate in cancer has been recently explained by the seminal work of the Vander Heiden group (<xref rid="bib66" ref-type="bibr">Sullivan et&#x000a0;al., 2015</xref>). Initially, <xref rid="bib66" ref-type="bibr">Sullivan et&#x000a0;al. (2015)</xref> demonstrated that in oxidative phosphorylation (OXPHOS)-proficient cells, respiration serves to fuel electron acceptors for aspartate synthesis, and aspartate&#x000a0;supplementation is sufficient to sustain proliferation in OXPHOS-deficient cells (<xref rid="bib69" ref-type="bibr">Tao et&#x000a0;al., 2011</xref>). More recently, 2 independent studies revealed that aspartate availability is a metabolic limitation that tumors experience and that overcoming this limitation, either via aspartate upload via SLC1A3 (<xref rid="bib25" ref-type="bibr">Garcia-Bermudez et&#x000a0;al., 2018</xref>) or via the conversion of asparagine into aspartate (<xref rid="bib67" ref-type="bibr">Sullivan et&#x000a0;al., 2018</xref>), is advantageous for tumor growth. Previous studies have reported that metformin anti-tumor activity correlates with a diminution of NAD<sup>+</sup> and aspartate in tumors (<xref rid="bib27" ref-type="bibr">Gui et&#x000a0;al., 2016</xref>), and these findings indicate that aspartate limitation is required for the anti-tumor efficacy of metformin and, broadly, other biguanides. We have previously reported that metformin was ineffective in AI-resistant models (<xref rid="bib3" ref-type="bibr">Bacci et&#x000a0;al., 2016</xref>), and this can now be explained by the enhanced SLC1A2-dependent aspartate-boosting mechanism that maintains aspartate homeostasis. Therefore, lowering aspartate intratumoral levels may be of benefit in ETR. However, as confirmed in our study, SLC1A2 can also serve for glutamate import, and only the concomitant deprivation of both amino acids was able to reduce the mitochondrial potential and OCR of the resistant cells. However, even if the glutamate contribution seems lower than that of aspartate by <sup>14</sup>C tracing experiments, flux analysis using U-<sup>13</sup>C-glutamate revealed a role for glutamate in anabolism, which is able to sustain not only DNA biosynthetic pathways but also lipid and protein biosynthesis. This anabolic supporting role of aspartate and glutamate is in line with previous reports showing that the majority of carbon mass in cells is derived from amino acids rather than glucose or glutamine (<xref rid="bib29" ref-type="bibr">Hosios et&#x000a0;al., 2016</xref>).</p><p id="p0125">In conclusion, the experimental and clinical data herein presented support a role for amino acid metabolism and availability in promoting ETR. The findings provide mechanistic insights into the metabolic deregulation of ETR and a series of molecular players that could be useful in identifying a signature for breast cancer patients with an increased risk of ETR. This is particularly pertinent given that the majority of ER<sup>+</sup> breast cancer patients will undergo ET and that the identification of resistant patients is an important and still unmet clinical issue.</p></sec><sec id="sec4"><title>STAR&#x02605;Methods</title><sec id="sec4.1"><title>Key Resources Table</title><p id="p0130"><table-wrap position="float" id="undtbl1"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Mouse monoclonal anti-tubulin</td><td>Sigma</td><td>Cat# T5168; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_477579" id="intref0020">AB_477579</ext-link></td></tr><tr><td>Rabbit polyclonal anti-GATA2</td><td>Cell signaling</td><td>Cat# 4595; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2108579" id="intref0025">AB_2108579</ext-link></td></tr><tr><td>Mouse monoclonal anti-SLC1A2</td><td>Santa Cruz Biotechnology</td><td>Cat# 365634; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_10844832" id="intref0030">AB_10844832</ext-link></td></tr><tr><td>Rabbit polyclonal anti-SLC6A14</td><td>Abcam</td><td>Cat# ab99102; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_10696963" id="intref0035">AB_10696963</ext-link></td></tr><tr><td>Rabbit polyclonal anti-beclin1</td><td>Thermo Fisher Scientific</td><td>Cat# PA1-16857; RRID:<ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_568459" id="intref0040">AB_568459</ext-link></td></tr><tr><td>Rabbit polyclonal anti-LC3</td><td>Thermo Fisher Scientific</td><td>Cat# PA1-16930; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2281384" id="intref0045">AB_2281384</ext-link></td></tr><tr><td>Mouse monoclonal anti-ubiquitin-K63</td><td>Thermo Fischer Scientific</td><td>Cat# 14-6077-80; RRID:<ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_1257214" id="intref0050">AB_1257214</ext-link></td></tr><tr><td>Mouse monoclonal anti-APG7</td><td>Santa Cruz Biotechnology</td><td>Cat# sc-376212 RRID:<ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_10988418" id="intref0055">AB_10988418</ext-link></td></tr><tr><td>Mouse monoclonal anti-beclin1</td><td>Santa Cruz Biotechnology</td><td>Cat# sc-48341 RRID:<ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_626745" id="intref0060">AB_626745</ext-link></td></tr><tr><td>Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor 488 conjugate</td><td>Thermo Fisher Scientific</td><td>Cat# A-11034; RRID:<ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2576217" id="intref0065">AB_2576217</ext-link></td></tr><tr><td>Goat Anti-Rabbit IgG (H+L) Highly Cross-adsorbed Antibody, Alexa Fluor 633 conjugate</td><td>Thermo Fisher Scientific</td><td>Cat# A-21071; RRID:<ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_141419" id="intref0070">AB_141419</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Biological Samples</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Patient-derived xenografts HBCx34</td><td>Prof. Elisabetta Marangoni</td><td><xref rid="bib13" ref-type="bibr">Cottu et&#x000a0;al., 2014</xref></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, Peptides, and Recombinant Proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Methanol</td><td>Sigma</td><td>Cat# 900688-1</td></tr><tr><td>Acetonitrile</td><td>Sigma</td><td>Cat# 34851</td></tr><tr><td>4-N,N-dimethylaminoazobenzene-4&#x02019;-sulfonyl chloride</td><td>Supelco</td><td>Cat# 502219</td></tr><tr><td>KH<sub>2</sub>PO<sub>4</sub></td><td>Sigma</td><td>Cat# P3786</td></tr><tr><td>Amino acids standards</td><td>Sigma</td><td>Cat# A9781</td></tr><tr><td>Chloroform</td><td>Sigma</td><td>Cat# 34854-1</td></tr><tr><td>Water</td><td>Merck</td><td>Cat# 102699-1000</td></tr><tr><td>Norvaline</td><td>Sigma</td><td>Cat# 53721</td></tr><tr><td>Methoxyamine hydrochloride</td><td>Sigma</td><td>Cat# 226904</td></tr><tr><td>Pyridine</td><td>Thermo Fisher Scientific</td><td>Cat# 25104</td></tr><tr><td><italic>N</italic>-Methyl-<italic>N</italic>-(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane</td><td>Sigma</td><td>Cat# 69478</td></tr><tr><td>Chloroquine diphosphate</td><td>Sigma</td><td>Cat# C6628</td></tr><tr><td>Glutamine</td><td>Sigma</td><td>Cat# G7513</td></tr><tr><td>RPMI 1640 medium</td><td>GIBCO</td><td>Cat# 11835-063</td></tr><tr><td>DMEM 1X</td><td>GIBCO</td><td>Cat# A14430-01</td></tr><tr><td><sup>14</sup>C-Glutamic acid</td><td>Perkin Elmer</td><td>Cat# NEC290E050UC</td></tr><tr><td><sup>14</sup>C-Aspartic acid</td><td>Perkin Elmer</td><td>Cat# NEC268E050UC</td></tr><tr><td><sup>14</sup>C-Amino Acid Mixture</td><td>Perkin Elmer</td><td>Cat# NEC850E050UC</td></tr><tr><td><sup>13</sup>C-Glutamic acid</td><td>Sigma</td><td>Cat# 604860</td></tr><tr><td><sup>13</sup>C-Aspartic acid</td><td>Cambridge Isotope Laboratories</td><td>Cat# CNLM-544-H-0.25</td></tr><tr><td>D-Glutamic acid</td><td>Sigma</td><td>Cat# G1001</td></tr><tr><td>L-Aspartic acid</td><td>Sigma</td><td>Cat# A9256</td></tr><tr><td>Z-4-hydroxytamoxifen</td><td>Sigma</td><td>Cat# H7904</td></tr><tr><td>17-&#x003b2;-estradiol</td><td>Sigma</td><td>Cat# E2758</td></tr><tr><td>Fulvestrant</td><td>Sigma</td><td>Cat# I4409</td></tr><tr><td>Lipofectamine RNAiMAX</td><td>Thermo Fisher Scientific</td><td>Cat# 13778-150</td></tr><tr><td>Opti-MEM</td><td>GIBCO</td><td>Cat# 31985062</td></tr><tr><td>Fetal Bovine Serum</td><td>Euroclone</td><td>Cat# ECS0180L</td></tr><tr><td>Charcoal/Dextran Treated FBS (DCC)</td><td>Hyclone</td><td>Cat# SH30068.03</td></tr><tr><td>Protease inhibitor cocktail</td><td>Sigma</td><td>Cat# P8340</td></tr><tr><td>Matrigel Matrix</td><td>BD Biosciences</td><td>Cat# 356234</td></tr><tr><td>Protein A/G-PLUS Agarose beads</td><td>Santa Cruz Biotechnology</td><td>Cat# sc-2003</td></tr><tr><td>DiffQuick solution</td><td>BD Biosciences</td><td>Cat# 726443</td></tr><tr><td>Laemmli Sample Buffer</td><td>Bio-Rad</td><td>Cat# 161-0737</td></tr><tr><td>Clarity Western ECL Substrate</td><td>Bio-Rad</td><td>Cat# 170-5061</td></tr><tr><td>XFe Seahorse RPMI medium</td><td>Agilent Technologies</td><td>Cat# 103336-100</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Critical Commercial Assays</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>TaqMan Universal Mastermix no UNG</td><td>Applied Biosystems</td><td>Cat# 4440040</td></tr><tr><td>QuantiTect Reverse Transcription Kit</td><td>QIAGEN</td><td>Cat# 205311</td></tr><tr><td>TaqMan MicroRNA Reverse Transcription Kit</td><td>Applied Biosystems</td><td>Cat# 43665967</td></tr><tr><td>miRNeasy Mini Kit</td><td>QIAGEN</td><td>Cat# 217004</td></tr><tr><td>SosAdvanced Universal Sybr Green Supermix</td><td>Bio-Rad</td><td>Cat# 1725270</td></tr><tr><td>Cayman Chemicals Protein Synthesis Assay</td><td>Cayman Chemical</td><td>Cat# 601100</td></tr><tr><td>Seahorse XF Cell Mito Stress Kit</td><td>Agilent Technologies</td><td>Cat# 103015-100</td></tr><tr><td>Human genome microarray</td><td>Agilent Technologies</td><td>Cat# G4851A</td></tr><tr><td>Human miRNA microarray v16</td><td>Agilent Technologies</td><td>Cat# G4870A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Deposited Data</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>mRNA and miRNA microarray data</td><td>This paper</td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE120931" id="intref0075">GSE120931</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib55" ref-type="bibr">R&#x000e8;me et&#x000a0;al., 2013</xref></td><td>ArrayExpress: <ext-link ext-link-type="uri" xlink:href="array-express:E-MTAB-365" id="intref0080">E-MTAB-365</ext-link></td></tr><tr><td>The Cancer Genome Atlas (TGCA)</td><td><ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga" id="intref0085">https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga</ext-link></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_003193" id="intref0090">SCR_003193</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib39" ref-type="bibr">Loi et&#x000a0;al., 2007</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE6532" id="intref0095">GSE6532</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib14" ref-type="bibr">Dedeurwaerder et&#x000a0;al., 2011</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE20711" id="intref0100">GSE20711</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib15" ref-type="bibr">Desmedt et&#x000a0;al., 2007</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE7390" id="intref0105">GSE7390</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib57" ref-type="bibr">Sabatier et&#x000a0;al., 2011</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE21653" id="intref0110">GSE21653</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib71" ref-type="bibr">Wang et&#x000a0;al., 2005</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2034" id="intref0115">GSE2034</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib64" ref-type="bibr">Sotiriou et&#x000a0;al., 2006</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2990" id="intref0120">GSE2990</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib68" ref-type="bibr">Symmans et&#x000a0;al., 2010</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE17705" id="intref0125">GSE17705</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib77" ref-type="bibr">Zhang et&#x000a0;al., 2009</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE12093" id="intref0130">GSE12093</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib40" ref-type="bibr">Loi et&#x000a0;al., 2008</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE9195" id="intref0135">GSE9195</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib44" ref-type="bibr">Miller et&#x000a0;al., 2005</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE3494" id="intref0140">GSE3494</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib30" ref-type="bibr">Karn et&#x000a0;al., 2010</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE4611" id="intref0145">GSE4611</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib50" ref-type="bibr">Nagalla et&#x000a0;al., 2013</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE45255" id="intref0150">GSE45255</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib46" ref-type="bibr">Minn et&#x000a0;al., 2005</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2603" id="intref0155">GSE2603</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib16" ref-type="bibr">Desmedt et&#x000a0;al., 2009</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE16391" id="intref0160">GSE16391</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib10" ref-type="bibr">Clarke et&#x000a0;al., 2013</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE42568" id="intref0165">GSE42568</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib19" ref-type="bibr">Filipits et&#x000a0;al., 2011</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE26971" id="intref0170">GSE26971</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib35" ref-type="bibr">Li et&#x000a0;al., 2010</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE19615" id="intref0175">GSE19615</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib45" ref-type="bibr">Miller et&#x000a0;al., 2007</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE5462" id="intref0180">GSE5462</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib43" ref-type="bibr">Massarweh et&#x000a0;al., 2011</xref></td><td>GEO: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE33658" id="intref0185">GSE33658</ext-link></td></tr><tr><td>Gene expression data</td><td><xref rid="bib53" ref-type="bibr">Pereira et&#x000a0;al., 2016</xref></td><td>METABRIC</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental Models: Cell Lines</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>MCF7</td><td>ATCC</td><td>Cat# HTB-22</td></tr><tr><td>ZR75.1</td><td>ATCC</td><td>Cat# CRL-1500</td></tr><tr><td>HCC1428</td><td>ATCC</td><td>Cat# CRL-2327</td></tr><tr><td>LTED Cells</td><td><xref rid="bib3" ref-type="bibr">Bacci et&#x000a0;al., 2016</xref></td><td>N/A</td></tr><tr><td>MCF7-TAMR</td><td>This paper</td><td>N/A</td></tr><tr><td>MCF7-FULVR</td><td>This paper</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental Models: Organisms/Strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>BALB/c mice</td><td>Charles River Laboratories</td><td>Cat# 236CB17SCID</td></tr><tr><td>NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)</td><td><xref rid="bib63" ref-type="bibr">Sim&#x000f5;es et&#x000a0;al., 2015</xref></td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Oligonucleotides</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>anti-miR<italic>-</italic>23b-3p</td><td>Ambion</td><td>Cat# MH10711</td></tr><tr><td>siSLC1A2</td><td>Sigma</td><td>Cat# Hs01_00109453</td></tr><tr><td>siCTR</td><td>Sigma</td><td>Cat# SIC001</td></tr><tr><td>anti-miR-negative control (anti-miR-CTR)</td><td>Ambion</td><td>Cat# AM17011</td></tr><tr><td>siGATA2</td><td>Sigma</td><td>Cat# Hs01_00106117</td></tr><tr><td>siATG7_71</td><td>Sigma</td><td>Cat# Hs02_00341471</td></tr><tr><td>siATG7_49</td><td>Sigma</td><td>Cat# Hs01_00077649</td></tr><tr><td>siATG7_48</td><td>Sigma</td><td>Cat# Hs01_00077648</td></tr><tr><td>SLC6A14 (Hs00924564_m1)</td><td>Applied Biosystems</td><td>Cat# 4448892</td></tr><tr><td>SLC1A2 (Hs01102423_m1)</td><td>Applied Biosystems</td><td>Cat# 4448892</td></tr><tr><td>GATA2 (Hs00231119_m1)</td><td>Applied Biosystems</td><td>Cat# 4453320</td></tr><tr><td>GAPDH (Hs02786624_g1)</td><td>Applied Biosystems</td><td>Cat# 4331182</td></tr><tr><td>ACTB (Id:Hs99999903_m1)</td><td>Applied Biosystems</td><td>Cat# 4331182</td></tr><tr><td>miR-23b-3-p (000400)</td><td>Applied Biosystems</td><td>Cat# 4427975</td></tr><tr><td>RNU48 (001006)</td><td>Applied Biosystems</td><td>Cat# 4427975</td></tr><tr><td>U6 (001973)</td><td>Applied Biosystems</td><td>Cat# 4427975</td></tr><tr><td>TNFAIP3 precast primer (HsaCID0012648)</td><td>Bio-Rad</td><td>Cat# 10025636</td></tr><tr><td>Beclin-1 precast primer (HsaCID0016032)</td><td>Bio-Rad</td><td>Cat# 10025636</td></tr><tr><td>GAPDH precast primer (HsaCED0038674)</td><td>Bio-Rad</td><td>Cat# 10025636</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Software and Algorithms</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Masshunter Quantitative Analysis Software</td><td>Agilent Technologies</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_015040" id="intref0190">SCR_015040</ext-link></td></tr><tr><td>Masshunter Qualitative Analysis</td><td>Agilent Technologies</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_016657" id="intref0195">SCR_016657</ext-link></td></tr><tr><td>Fihen Metabolomics RTL library</td><td>Agilent Technologies</td><td>Cat# G1676AA</td></tr><tr><td>7500 Real-Time PCR Software</td><td>Applied Biosystems</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_014596" id="intref0200">SCR_014596</ext-link></td></tr><tr><td>Thermo XCalibur Quan Browser software</td><td>Thermo Fisher Scientific</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_014593" id="intref0205">SCR_014593</ext-link></td></tr><tr><td>FiJi</td><td><ext-link ext-link-type="uri" xlink:href="https://fiji.sc" id="intref0210">https://fiji.sc</ext-link></td><td>N/A</td></tr><tr><td>GraphPad Prism v8.0c</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/" id="intref0215">https://www.graphpad.com/</ext-link></td><td>N/A</td></tr><tr><td>KM plotter</td><td><xref rid="bib79" ref-type="bibr">Gy&#x000f6;rffy et&#x000a0;al., 2010</xref>, <xref rid="bib34" ref-type="bibr">L&#x000e1;nczky et&#x000a0;al., 2016</xref></td><td><ext-link ext-link-type="uri" xlink:href="http://kmplot.com/analysis/" id="intref0220">http://kmplot.com/analysis/</ext-link></td></tr><tr><td>cBioPortal</td><td><ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/" id="intref0225">https://www.cbioportal.org/</ext-link></td><td>RRID:<ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_014555" id="intref0230">SCR_014555</ext-link></td></tr><tr><td>Firebrowse</td><td><ext-link ext-link-type="uri" xlink:href="http://firebrowse.org/" id="intref0235">http://firebrowse.org/</ext-link></td><td>N/A</td></tr><tr><td>Seahorse Wave software</td><td>Agilent Technologies</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_014526" id="intref0240">SCR_014526</ext-link></td></tr><tr><td>GeneSpring GX v.14.8 software</td><td>Agilent Technologies</td><td>RRID:<ext-link ext-link-type="uri" xlink:href="rridsoftware:SCR_010972" id="intref0245">SCR_010972</ext-link></td></tr><tr><td>R Statistical Software</td><td><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/" id="intref0250">https://www.r-project.org/</ext-link></td><td>N/A</td></tr></tbody></table></table-wrap></p></sec><sec id="sec4.2"><title>Lead Contact and Materials Availability</title><p id="p0135">Further information and requests for resources and reagents should be directed to and will be made available upon reasonable request by the Lead Contact, Andrea Morandi (<ext-link ext-link-type="uri" xlink:href="mailto:andrea.morandi@unifi.it" id="intref0255">andrea.morandi@unifi.it</ext-link>).</p></sec><sec id="sec4.3"><title>Experimental Model and Subject Details</title><sec id="sec4.3.1"><title>Cell Culture</title><p id="p0140">MCF7, ZR75.1 and HCC1428 human female breast cancer cells were obtained from ATCC and cultured in phenol red-free RPMI 1640&#x000a0;medium (GIBCO #11835-063) supplemented with 10% fetal bovine serum (FBS, Euroclone #ECS0180L) 2&#x000a0;mmol/L glutamine (Sigma #G7513) and 1&#x000a0;nmol/L 17&#x003b2;-estradiol (E2, Sigma #E2758). The corresponding LTED (long term estrogen deprived) derivatives were maintained in sterol-deprived medium in phenol red&#x02013;free RPMI1640 medium containing 10% dextran charcoal-stripped FBS (Hyclone #SH30068.03) and 2&#x000a0;mmol/L glutamine (DCC medium). Tamoxifen- (TAMR) and fulvestrant- (FULVR) resistant cells were cultured in DCC medium supplemented with 1&#x000a0;&#x003bc;mol/L 4-OH tamoxifen (Sigma #H7904) or 100&#x000a0;nmol/L fulvestrant (Sigma #I4409), respectively. Cells were short tandem repeat tested, amplified, stocked, routinely subjected to mycoplasma testing and once thawed were kept in culture for a maximum of 20 passages.</p></sec><sec id="sec4.3.2"><title>Mouse models and care</title><p id="p0145">5- to 6-week-old female BALB/c mice were purchased from Charles River Laboratories (236CB17SCID) and used for tail vein injection experiments. Animal work was carried out under the Project licenses 1002/2017-PR and was approved by the <italic>Ministero della Salute</italic>. All animals were monitored by staff from the <italic>Centro Stabulazione Animali da Laboratorio</italic> (CESAL) for signs of ill health. Mice were housed under sterile conditions (five or less animals per cage) with <italic>ad libitium</italic> access to food and water.</p><p id="p0150">For patient-derived xenografts (PDX), mouse studies were conducted in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986, using 8- to 10-week-old NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) female mice at the University of Manchester. HBCx34 and HBCx34 TAMR PDXs have been established as previously described (<xref rid="bib13" ref-type="bibr">Cottu et&#x000a0;al., 2014</xref>). Serial passaging of the PDX was carried out by implanting small fragments of the tumor subcutaneously into dorsal flanks of NSG mice. HBCx34 breast cancer estrogen-dependent PDXs were administered with 8&#x000a0;&#x003bc;g/ml of E2 in drinking water at all times. HBCx34 TAMR PDXs were treated for the entire duration of the experiments in the presence of tamoxifen (10&#x000a0;mg/kg/day, oral gavage). Experiments were performed using PDX tumors between passages 5 and 8. Animal weight and tumor size were measured twice a week. Tumor chunks were snap frozen and further processed for either RNA extraction and qRT-PCR analysis or GC-MS.</p></sec></sec><sec id="sec4.4"><title>Method Details</title><sec id="sec4.4.1"><title>Cell viability assay</title><p id="p0155">Sensitive and resistant cells were seeded into 12 well plates in either standard conditions (see cell culture) or experimental conditions such as in the presence of 25&#x000a0;&#x003bc;mol/l of the autophagy inhibitor CQ (Sigma #C6628). 5&#x000a0;days post seeding cells, plates were stained with crystal violet (triphenylmethane dye 4-[(4-dimethylaminophenyl)-phenyl-methyl]-N,N-dymethyl-alanine; Sigma #548-62-9), dried overnight and the crystal violet within the adherent cells solubilized with 500&#x000a0;&#x003bc;l/well of 2% SDS. The absorbance at 595&#x000a0;nm was evaluated using a microplate reader.</p></sec><sec id="sec4.4.2"><title>MTT assay</title><p id="p0160">Sensitive and resistant cells transfected using siRNA against ATG7 were seeded into 24 well plates in standard medium (see cell culture). 48 hours after transfection cells were subjected to the colorimetric non-radioactive quantification of cell proliferation and viability using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (0,2mg/ml, Sigma #M5655). MTT was added into the medium of each well and after 2 hours at 37&#x000b0;C, the cells were extensively washed with PBS, allow to dry and then 200&#x000a0;&#x003bc;L of DMSO was added to resuspended the amount of MTT within the cells and 100&#x000a0;&#x003bc;L was subjected to absorbance wavelength evaluation at 565&#x000a0;nm using a microplate reader.</p></sec><sec id="sec4.4.3"><title>Colony formation assay</title><p id="p0165">To evaluate clonogenicity of breast cancer cells under stress conditions, 0.5-1&#x000a0;&#x000d7; 10<sup>3</sup> cells were seeded per well in a 6 well plate in either the recommended medium conditions or experimental conditions such as amino acids deprivation. 15&#x000a0;days post seeding, the colonies were fixed with 4% formaldehyde and stained with crystal violet staining solution. Air-dried plates were scanned at 600 dpi and images analyzed using FiJi.</p></sec><sec id="sec4.4.4"><title>Transwell invasion assay</title><p id="p0170">Invasion assay was performed using 8-&#x003bc;m-pore transwells (Corning #3428) coated with 10&#x02009;&#x003bc;g/cm<sup>2</sup> of reconstituted standard formulation Matrigel (BD Biosciences #356334). Transfected cells (using anti-miR-23b-3p, siSLC1A2 and relative controls oligos) were serum starved for 6 hours and then 1&#x000a0;&#x000d7; 10<sup>5</sup> cells seeded onto the upper chamber of the transwell in serum-free medium and allow to invade overnight toward complete medium. Air-dried membranes stained with DiffQuick solution (BD Biosciences #726443) were imaged and invasion was evaluated by counting the cells migrated to the lower surface of the filters (six randomly chosen fields).</p></sec><sec id="sec4.4.5"><title>Protein <italic>de novo</italic> synthesis assay</title><p id="p0175">To analyze protein <italic>de novo</italic> synthesis rate in resistant cells compared to parental cells, 3&#x000a0;&#x000d7; 10<sup>4</sup> cells were seeded per well in a 96 well clear bottom black plate (Corning #3603). The following day, the culture media were removed and cells were incubated for 30&#x000a0;minutes in fresh culture medium containing O-Propargyl-Puromycin (OPP) with or without 50&#x000a0;&#x003bc;g/ml cycloheximide. OPP incorporates into the C terminus of translating polypeptide chains, thereby stopping translation. The truncated C-terminal alkyne-labeled proteins can subsequently be detected via copper-catalyzed click chemistry (<xref rid="bib37" ref-type="bibr">Liu et&#x000a0;al., 2012</xref>). Cells were then processed for detection of protein synthesis according to the protocol of Cayman Chemicals Protein Synthesis assay (Cayman Chemicals #601100).</p></sec><sec id="sec4.4.6"><title>RNAi transfection</title><p id="p0180">Cells were transfected with 15&#x000a0;nmol/L anti-miR<italic>-</italic>23b-3p (MH10711, Ambion), with 45&#x000a0;nmol/L siSLC1A2 (Hs01_00109453, Sigma), siGATA2 (Hs01_00106117, Sigma), or siATG7 (Hs02_00341471, Hs01_00077649, or Hs01_00077648, Sigma) and respective negative controls (AM17011, Ambion; SIC001, Sigma) using Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific #13778-150) and Opti-MEM (GIBCO #31985062) accordingly to manufacturer&#x02019;s instructions and analysis was performed 3&#x000a0;days after transfection.</p></sec><sec id="sec4.4.7"><title>Radioactive assays</title><p id="p0185">Breast cancer cells were treated as described in the figures for 3&#x000a0;days (see RNAi transfection). Aspartic acid, glutamic acid or amino acids uptake was evaluated incubating the cells with uptake buffer solution (140&#x000a0;mmol/L NaCl, 20&#x000a0;mmol/L HEPES/Na, 2.5&#x000a0;mmol/L MgSO<sub>4</sub>, 1&#x000a0;mmol/L CaCl<sub>2</sub>, and 5&#x000a0;mmol/L KCl, pH 7.4) containing [U-<sup>14</sup>C] radioactive metabolites for 15&#x000a0;minutes. Cells were subsequently washed with ice cold PBS and lysed with 0.1 mol/L NaOH.</p><p id="p0190">To analyze the incorporation of radioactive amino acids into proteins, lipids or DNA, culture media were changed to a deprived-DMEM medium (GIBCO #A14430-01) with or without non-radioactive amino acids in the presence of 10% DCC, 11&#x000a0;mM glucose, 2&#x000a0;mmol/L glutamine and then supplemented with 1&#x000a0;&#x003bc;Ci <sup>14</sup>C-aspartic acid (Perkin Elmer # NEC268E050UC) or 1.5&#x000a0;&#x003bc;Ci <sup>14</sup>C-glutamic acid (Perkin Elmer # NEC850E050UC) 24 hours prior to the end of the experiment. For radioactive incorporation into proteins, cells were washed in ice cold PBS and then resuspended in 20% trichloroacetic acid, placed on ice for 30&#x000a0;minutes and centrifuged (10000&#x000a0;rpm for 10&#x000a0;minutes at 4&#x000b0;C). Pellet was resuspended in dH<sub>2</sub>O, transferred to a scintillation vial and counted on the scintillation counter. For fatty acids synthesis analysis, cells were washed three times in ice cold PBS and then lysed in methanol. Samples were first resuspended in 4 volumes of a CHCl<sub>3</sub>:MeOH (1:1) solution and then an additional volume of dH<sub>2</sub>O was added. The solution was then centrifuged at 1000&#x000a0;rpm for 5&#x000a0;minutes at room temperature. The lower phase was collected, transferred to a scintillation vial and&#x000a0;counted on the scintillation counter. For DNA incorporation analysis, cells were washed and then resuspended in Tris-Hcl 50mM/EDTA 100mM/SDS 0.5%/proteinase K lysis buffer. Samples were added to one volume of phenol:chloroform:isoamyl alcohol (25:24:1), mixed and centrifuged (10000&#x000a0;rpm for 10&#x000a0;minutes at room temperature). The upper aqueous phase was collected, resuspended in 1/10 volume of 3&#x000a0;M NH<sub>4</sub>OAc and 2 volumes of ethanol and incubated for 3 hours at &#x02212;80&#x000b0;C. The precipitated DNA was pelleted (10000&#x000a0;rpm for 10&#x000a0;minutes at room temperature), washed with 70% ethanol and allowed to dry. The pellet was resuspended in dH<sub>2</sub>O and transferred to a scintillation vial and counted on the scintillation counter. All the radioactive signals were normalized on protein content.</p></sec><sec id="sec4.4.8"><title>Immunoblotting and immunoprecipitation</title><p id="p0195">Cells were lysed using cold RIPA buffer (50&#x000a0;mM Tris Hcl pH7.5, 150&#x000a0;mM NaCL, 1% Nonidet P-40,2&#x000a0;mM EGTA, 1&#x000a0;mM sodium ortovanadate, 100&#x000a0;mM NaF) supplemented with protease inhibitors (Sigma # P8340) and protein concentrations of lysate were measured by Bradford method (Bio-Rad Protein Assay #500-006), 20-40&#x000a0;&#x003bc;g of total proteins were loaded in precast SDS-PAGE gels (Biorad #456-8096) and then transferred onto nitrocellulose membrane by Trans-Blot Turbo Transfer Pack (Biorad #1704157). The immunoblots were incubated in non-fat dry milk 2%, tween 20 0.05% in PBS at room temperature and probed with primary and appropriate secondary antibodies. The antibodies used in immunoblotting were GATA2 (Cell Signaling, #4595S) and SLC1A2 (Santa Cruz Biotechnology, #sc-365634), SLC6A14 (Abcam, #ab99102), beclin-1 (Invitrogen, #PA1-16857), LC3 (Invitrogen, #PA1-16930) and ubiquitin-K63 (Thermo Fisher, #14-6077-80), APG7 (Santa Cruz Biotechnology, #sc-376212), tubulin (Sigma, #T5168).</p><p id="p0200">Immunoprecipitation was performed using the Protein A/G-PLUS Agarose beads (Santa Cruz Biotechnology #sc-2003) according to the manufacturer&#x02019;s instructions. Briefly, 300&#x000a0;&#x003bc;g of cell lysate were incubated overnight with beclin-1 antibody (Santa Cruz Biotechnology, sc-48341) prior to incubating the protein:antibody complex with the beads. Immunoprecipitated proteins:antibody:beads complexes were dissociated using Laemmli buffer (Bio-Rad #161-0737) and subjected to SDS-PAGE.</p></sec><sec id="sec4.4.9"><title>Immunofluorescence</title><p id="p0205">Glass coverslip (Nunc LabTek&#x000ae; Chambered CoverGlass, Thermo Scientific)-plated cells were fixed with 4% formaldehyde for 1&#x000a0;hours, then permeabilized with 0.1% Triton in PBS before incubation with primary antibodies. Primary antibodies were diluted in blocking solution 1/400 (1% BSA and 2% serum in PBS) and incubated overnight at 4&#x000b0;C. Secondary antibodies conjugated with Alexa Fluor 488 (Life Technologies, goat anti-rabbit #A-11034) or 633 (Life Technologies, goat anti-rabbit #A-21071) were diluted in blocking solution (1/1000) and incubated for 1 hour at room temperature. All fluorescence samples were examined at room temperature using a microscope (TCS SP5; Leica) with lasers exciting at 488, 543, and 633&#x000a0;nm (Leica). Lasers and spectral detection bands were chosen for the optimal imaging of Alexa Fluor 488 and 633 signals. PMT levels were set using control samples. Multicolor images were collected simultaneously in two or three channels. Images were taken using a 20x/NA/air 40x/1.25 NA oil HCX Plan Apo and 63x, 1.4&#x02013;0.6 NA, oil, HCX Plan APO lens. Images were captured using the Leica LAS-AF image acquisition software. Overlays were generated using LAS-AF software. Photo montages were generated using LAS-AF, but were not further processed. The quantification was performed using FiJi: an outline was drawn around each cell and spots were counted in at least 50 cells derived from three representative 63x images from 3 independent experiments (one per experiment).</p></sec><sec id="sec4.4.10"><title>Real Time RT-PCR (qRT-PCR) and miRNA analysis</title><p id="p0210">Total RNA, including small RNAs, was extracted using miRNeasy (QIAGEN #217004), quantified and 500&#x000a0;ng were reverse transcribed using the QuantiTect high capacity cDNA reverse transcription kit (QIAGEN #205311), for mRNA analysis, or 10&#x000a0;ng using Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems #43665967), for miRNA analysis. qRT-PCR was done using a 7500 Fast Real Time PCR system (Applied Biosystems) using Taqman gene/microRNA assays (Applied Biosystems), respectively. The probes used in the work are: SLC6A14 (Hs00924564_m1), SLC1A2 (Hs01102423_m1), GATA2 (Hs00231119_m1) and endogenous controls GAPDH (Hs02786624_g1) and ACTB (Hs99999903_m1)) for mRNA analysis. For microRNA assay the probes used are miR-23b-3p (ID:000400), and endogenous control RNU 48 (ID:001006) and U6 (ID:001973). TNFAIP3 (HsaCID0012648, Bio-Rad) and beclin-1 (HsaCID0016032, Bio-Rad) mRNA expression analysis was performed using SYBR green dye precast primers (Bio-Rad) and normalized on the results obtained using GAPDH (HsaCED0038674, Bio-Rad). The relative quantity was determined using &#x00394;&#x00394;Ct, according to the manufacturer&#x02019;s instructions (Applied Biosystems).</p></sec><sec id="sec4.4.11"><title>Seahorse XF MitoStress Test</title><p id="p0215">Cells were seeded in XFe96 cell culture plates with 1.5-2&#x000a0;&#x000d7; 10<sup>4</sup> cells per well in 80&#x000a0;&#x003bc;L of culture medium and incubated at 37&#x000b0;C (5-8 technical replicates). 24 hours post seeding medium was replaced with 180&#x000a0;&#x003bc;L XF base medium supplemented with 25&#x000a0;mM glucose (Sigma #G8644), 2&#x000a0;mM glutamine, 1&#x000a0;mM sodium pyruvate (Sigma #S8636). Cells were incubated for 1 hour at 37&#x000b0;C in atmospheric CO<sub>2</sub> to allow the cells to pre-equilibrate with the XF base medium. An accurate titration with the uncoupler FCCP was performed for&#x000a0;each cell type. Together with OCR measurement, values of ECAR were also recorded. Addition of Aspartate (0.15&#x000a0;mM, Sigma&#x000a0;#A9256), Glutamate (0.13&#x000a0;mM Sigma #G1001), the ATP synthase inhibitor oligomycin (0.8&#x000a0;&#x003bc;M), the proton uncoupler FCCP (0.5-1&#x000a0;&#x003bc;M), the respiratory complex I inhibitor rotenone (1&#x000a0;&#x003bc;M), and the respiratory complex III inhibitor antimycin A (1&#x000a0;&#x003bc;M) was carried out at the times indicated. Protein quantification was used to normalize the results. Basal respiration is calculated as last rate measurement before injection &#x02013; non-mitochondrial respiration rate. Maximal respiration is calculated as the maximum rate measurement after FCCP injection &#x02013; non-mitochondrial respiration.</p></sec><sec id="sec4.4.12"><title>High-performance liquid chromatography (HPLC)</title><p id="p0220">Amino acids extraction was performed as reported by <xref rid="bib51" ref-type="bibr">Nemkov et&#x000a0;al. (2015)</xref>. Briefly, cell pellets were extracted immediately before analysis in ice-cold lysis/extraction buffer (methanol/acetonitrile/water, 5/3/2 v/v, Sigma) at a ratio of 2&#x000a0;&#x000d7; 10<sup>6</sup> cells/ml. Tubes were first agitated at 4&#x000b0;C for 30&#x000a0;minutes and then centrifuged at 4&#x000b0;C, 10000&#x000a0;g for 10&#x000a0;minutes. The recovered supernatants were subjected to precolumn derivatization of amino acids using 4-N,N-dimethylaminoazobenzene-4&#x02019;-sulfonyl chloride (Supelco #502219) following the manufacture instructions (DABS, Sigma). DABS-amino acids were detected at visible light wavelengths (436nm) using a DIONEX P680-UVD170U HPLC system (column: Kinetex 5&#x003bc;m C18 100&#x000a0;&#x000c5; LC column 250x4.6mm; mobile phase: A&#x000a0;= KH<sub>2</sub>PO<sub>4</sub> 25mM pH 6.8 (Sigma), B&#x000a0;= acetonitrile (Sigma #34851); gradient program (time:%B): 0-5&#x000a0;min: 20%; 5-9&#x000a0;min: 25%; 9-15&#x000a0;min: 25%; 15-18&#x000a0;min 30%; 18-22 30%; 22-27 35%; 27-35 60%; 35-43 70%; flow rate: 0.8ml/min; injection volume: 10&#x003bc;l). A reference amino acids spectrum was obtained by titrating a mixture of amino acids of known concentration (Sigma # A9781).</p></sec><sec id="sec4.4.13"><title>Gas chromatography&#x02013;MS (GC-MS)</title><p id="p0225">Snap frozen tissue samples were minced and subjected to extraction using a mixture of CHCl<sub>3</sub>:MeOH:H<sub>2</sub>O (Sigma #34854-1 and #900688-1, Merck #102699-1000) (1:1:1). Minced tissues were quenched with 0.4&#x000a0;mL ice cold methanol and an equal volume of water containing 1&#x000a0;&#x003bc;g norvaline (Sigma #53721), used as internal standard. One volume of chloroform was added, and the samples were vortexed at 4&#x000b0;C for 30&#x000a0;minutes. Samples were centrifuged at 3000&#x000a0;g for 10&#x000a0;minutes, and the aqueous phase was collected in a new tube and evaporated at room temperature. Dried polar metabolites were dissolved in 60&#x000a0;&#x003bc;L of 2% methoxyamine hydrochloride (Sigma #226904) in pyridine (25104 Thermo), and held at 30&#x000b0;C for 2 hours. After dissolution and reaction, 90&#x000a0;&#x003bc;L MSTFA&#x000a0;+ 1% TMCS (69478-10x Sigma) were added and samples were incubated at 37&#x000b0;C for 60&#x000a0;minutes. Gas chromatographic runs were performed with helium as carrier gas at 0.6&#x000a0;mL/min. The split inlet temperature was set to 250&#x000b0;C and the injection volume of 1&#x000a0;&#x003bc;L. A split ratio of 1:10 was used. The GC oven temperature ramp was from 60&#x000b0;C to 325&#x000b0;C at 10&#x000b0;C/min. The data acquisition rate was 10&#x000a0;Hz. For the Quadrupole, an EI source (70 eV) was used, and full-scan spectra (mass range from 50 to 600) were recorded in the positive ion mode. The ion source and transfer line temperatures were set, respectively, to 250&#x000b0;C and 290&#x000b0;C. The MassHunter data processing tool (Agilent) was used to obtain a global metabolic profiling. Fihen Metabolomics RTL library (Agilent G1676AA)</p></sec><sec id="sec4.4.14"><title><sup>13</sup>C-tracing experiments using liquid-chromatography-MS (LC-MS)</title><p id="p0230">Parental and LTED MCF7 cells were incubated for 48 hours with 0.15&#x000a0;mM [U-<sup>13</sup>C]-aspartic acid (Cambridge Isotope Laboratories) or 0.13&#x000a0;mM [U-<sup>13</sup>C]-L-glutamic acid (Sigma Aldrich). The cells were washed once with ice cold 0.9% NaCl solution. The metabolite extraction was performed using 80% methanol. After 5&#x000a0;minutes of incubation cells were scraped and collected in a new tube. Following a centrifugation at 20000&#x000a0;g for 10&#x000a0;minutes at 4&#x000b0;C, the supernatant was transferred to a new vial for MS analysis. Pellet was used for protein quantification. 5&#x000a0;&#x003bc;l of each sample was loaded into a Dionex UltiMate 3000 LC System (Thermo Scientific Bremen) equipped with a C-18 column (Acquity UPLC -HSS T3 1. 8&#x000a0;&#x003bc;m; 2.1&#x000a0;&#x000d7; 150&#x000a0;mm, Waters) coupled to a Q Exactive Orbitrap mass spectrometer (Thermo Scientific) operating in negative ion mode. A step gradient was carried out using solvent A (10&#x000a0;mM TBA and 15&#x000a0;mM acetic acid) and solvent B (100% methanol). The gradient started with 0% of solvent B and 100% solvent A and remained at 0% B until 2&#x000a0;minutes post injection. A linear gradient to 37% B was carried out until 7&#x000a0;minutes and increased to 41% until 14&#x000a0;minutes. Between 14 and 26&#x000a0;minutes the gradient increased to 100% of B and remained at 100% B for 4&#x000a0;minutes. At 30&#x000a0;minutes the gradient returned to 0% B. The chromatography was stopped at 40&#x000a0;minutes. The flow was kept constant at 250&#x000a0;&#x003bc;L/min and the column was placed at 25&#x000b0;C throughout the analysis. The MS operated in full scan - SIM (negative mode) using a spray voltage of 3.2 kV, capillary temperature of 320&#x000b0;C, sheath gas at 10.0, auxiliary gas at 5.0. For full scan - SIM mode, AGC target was set at 1e6 using a resolution of 70.000, with a maximum IT of 256&#x000a0;ms. For the data analyses we integrated the peak areas using the Thermo XCalibur Quan Browser software (Thermo Scientific).</p></sec><sec id="sec4.4.15"><title>Lung retention assay</title><p id="p0235">MCF7-LTED anti-miR-CTR, anti-miR-23b-3p, siCTR and siSLC1A2 cells were labeled with CellTracker Red CMTPX or Green CMFDA dyes (Molecular Probes), trypsinized, mixed at a 1:1 ratio, and a total of 1&#x000a0;&#x000d7; 10<sup>6</sup> cells injected into the tail veins of 5- to 6-week-old BALB/c mice. Mice were sacrificed at 1 and 5 hours post injection, and lungs were examined on a Leica TCS SP5 microscope using x10 lens. Six images were taken for each lung. Tumor cell colonization of the lung was quantified in the Fiji open platform for image analysis, by converting the red and green images into separate binary images and measuring total tumor cell coverage per field of view.</p></sec><sec id="sec4.4.16"><title>Gene and miRNA expression analysis</title><p id="p0240">MCF7 cells were cultured in either the recommended medium conditions or E2 deprived for 3&#x000a0;days and compared to MCF7-LTED cells cultured in standard medium. Triplicate samples from 3 independent experiments were assessed for global miRNA and gene expression by Microarrays. Specifically, 9 samples were hybridized on Agilent whole human genome microarray (Agilent Technologies #G4851A), which represents 60k unique human transcripts. The same samples were hybridized also on Agilent human miRNA microarray v16 (Agilent Technologies #G4870A). One-color gene expression was performed according to the manufacturer&#x02019;s procedure as previously described (<xref rid="bib18" ref-type="bibr">Ferracin et&#x000a0;al., 2013</xref>).</p></sec><sec id="sec4.4.17"><title>Bioinformatic analyses</title><p id="p0245">Microarray data were normalized and analyzed using GeneSpring GX v.14.8 software (Agilent Technologies). Data transformation was applied to set&#x000a0;all the negative raw values at 1.0, then the quantile normalization was applied. The probes detected in at least one sample were used for statistical analyses. Differentially expressed genes were selected to have a &#x02265; 2-fold expression difference between groups and an adjusted <italic>P</italic>-value &#x02264; 0.05 at ANOVA test, with Benjamini and Hoechberg correction. Supervised hierarchical clustering was performed for OS samples with GeneSpring clustering tool using the list of differentially expressed genes and Euclidean correlation as a measure of similarity.</p><p id="p0250">The mRNA and miRNA anti-correlation network analyses described in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C were performed using the R software. Briefly, mRNAs and miRNAs found as differentially expressed in each pairwise comparison (FDR&#x000a0;&#x0003c; 0.05, FC&#x000a0;&#x0003c; &#x02212;2 or &#x0003e; 2) were initially used to filter candidate interactors emerging from the PITA miRNA/target predictor tool (<xref rid="bib32" ref-type="bibr">Kertesz et&#x000a0;al., 2007</xref>). To ensure the identification of relevant interactors and limit the size of the network, the filtered collection of mRNA/miRNA pairs was further purged from experimentally validated pairs, according to the miRTarBase repository (<xref rid="bib9" ref-type="bibr">Chou et&#x000a0;al., 2018</xref>). The expression values of the remaining candidate interactors (taken from the whole set of samples rather than from those relevant for the differentially expressed analysis) were tested for mRNA/miRNA expression anti-correlation (correlation test, Benjamini-Hochberg correction, adjusted p&#x000a0;&#x0003c; 0.05 and correlation&#x000a0;&#x0003c; 0). The resulting networks were graphically annotated and represented using functions from the igraph R package.</p></sec><sec id="sec4.4.18"><title>Analysis of human datasets</title><p id="p0255">The BRCA TCGA dataset analyzed in <xref rid="fig1" ref-type="fig">Figures 1</xref>A, 1B, and <xref rid="fig4" ref-type="fig">4</xref>I is available in The Cancer Genome Atlas (TCGA) data portal (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga" id="intref0260">https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga</ext-link>). Gene and miRNA expression data and the corresponding clinical information for ER+ BRCA from TCGA provisional dataset were obtained through Firebrowse (<ext-link ext-link-type="uri" xlink:href="http://firebrowse.org/" id="intref0265">http://firebrowse.org/</ext-link>) data portal. The normalized reads count for mRNA (RSEM) and mature miRNAs (RPM) were downloaded and log<sub>2</sub> transformed. From the BRCA dataset, we selected samples with miRNA-mRNA and overall survival (OS) data. Survival analysis was performed using Kaplan-Meier curve log-rank testing, using Cutoff finder (<xref rid="bib6" ref-type="bibr">Budczies et&#x000a0;al., 2012</xref>) for best miR-23b-3p/SLCA6A14 high- and low-expression selection. For mRNA analysis in <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>C, overall survival (OS) of untreated breast cancer patients belonging to the METABRIC dataset were retrieved using Km-plotter (<ext-link ext-link-type="uri" xlink:href="http://kmplot.com" id="intref0270">http://kmplot.com</ext-link>) (<xref rid="bib34" ref-type="bibr">L&#x000e1;nczky et&#x000a0;al., 2016</xref>). For <italic>SLC6A14</italic> (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>B), <italic>TNFAIP3</italic> (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>E) survival analysis, the curated dataset of ER+ breast cancers was created using Km-plotter and included the relapse free survival data of patients belonging to the following datasets: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE6532" id="intref0275">GSE6532</ext-link> (<xref rid="bib39" ref-type="bibr">Loi et&#x000a0;al., 2007</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE20711" id="intref0280">GSE20711</ext-link> (<xref rid="bib14" ref-type="bibr">Dedeurwaerder et&#x000a0;al., 2011</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE7390" id="intref0285">GSE7390</ext-link> (<xref rid="bib15" ref-type="bibr">Desmedt et&#x000a0;al., 2007</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE21653" id="intref0290">GSE21653</ext-link> (<xref rid="bib57" ref-type="bibr">Sabatier et&#x000a0;al., 2011</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:E-MTAB-365" id="intref0295">E-MTAB-365</ext-link> (<xref rid="bib55" ref-type="bibr">R&#x000e8;me et&#x000a0;al., 2013</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2034" id="intref0300">GSE2034</ext-link> (<xref rid="bib71" ref-type="bibr">Wang et&#x000a0;al., 2005</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2990" id="intref0305">GSE2990</ext-link> (<xref rid="bib64" ref-type="bibr">Sotiriou et&#x000a0;al., 2006</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE17705" id="intref0310">GSE17705</ext-link> (<xref rid="bib68" ref-type="bibr">Symmans et&#x000a0;al., 2010</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE12093" id="intref0315">GSE12093</ext-link> (<xref rid="bib77" ref-type="bibr">Zhang et&#x000a0;al., 2009</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE9195" id="intref0320">GSE9195</ext-link> (<xref rid="bib40" ref-type="bibr">Loi et&#x000a0;al., 2008</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE3494" id="intref0325">GSE3494</ext-link> (<xref rid="bib44" ref-type="bibr">Miller et&#x000a0;al., 2005</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE4611" id="intref0330">GSE4611</ext-link> (<xref rid="bib30" ref-type="bibr">Karn et&#x000a0;al., 2010</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE45255" id="intref0335">GSE45255</ext-link> (<xref rid="bib50" ref-type="bibr">Nagalla et&#x000a0;al., 2013</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2603" id="intref0340">GSE2603</ext-link> (<xref rid="bib46" ref-type="bibr">Minn et&#x000a0;al., 2005</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE16391" id="intref0345">GSE16391</ext-link> (<xref rid="bib16" ref-type="bibr">Desmedt et&#x000a0;al., 2009</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE42568" id="intref0350">GSE42568</ext-link> (<xref rid="bib10" ref-type="bibr">Clarke et&#x000a0;al., 2013</xref>), <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE26971" id="intref0355">GSE26971</ext-link> (<xref rid="bib19" ref-type="bibr">Filipits et&#x000a0;al., 2011</xref>) and <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE19615" id="intref0360">GSE19615</ext-link> (<xref rid="bib35" ref-type="bibr">Li et&#x000a0;al., 2010</xref>).</p><p id="p0260">For <italic>GATA2</italic> (209710_at; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>I) overall survival analysis the curated dataset comprises the following datasets: <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE20711" id="intref0365">GSE20711</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE7390" id="intref0370">GSE7390</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE45255" id="intref0375">GSE45255</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE42568" id="intref0380">GSE42568</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE3494" id="intref0385">GSE3494</ext-link>. For <italic>SLC6A14</italic> (219795_at; <xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>G), <italic>TNFAIP3</italic> (202643_s_at; <xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>H) survival analysis, the curated dataset of ER+ breast cancers that have been treated with adjuvant tamoxifen was created using Km-plotter and included patients that belong to the following datasets <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE6532" id="intref0390">GSE6532</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE2990" id="intref0395">GSE2990</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE17705" id="intref0400">GSE17705</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE12093" id="intref0405">GSE12093</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE9195" id="intref0410">GSE9195</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE45255" id="intref0415">GSE45255</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE16391" id="intref0420">GSE16391</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE3494" id="intref0425">GSE3494</ext-link>, <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE26971" id="intref0430">GSE26971</ext-link> and <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE19615" id="intref0435">GSE19615</ext-link>. SLC1A2 data in 52 paired ER+ breast cancer samples pre- and post-2-week letrozole treatment (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>I) were retrieved using GEO (GSE5462) (<xref rid="bib45" ref-type="bibr">Miller et&#x000a0;al., 2007</xref>) and normalized log2 expression values are shown either pre- or post letrozole treatment for each patient. Correlation data on patients that have been treated with adjuvant fulvestrant (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>J) were from the <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE33658" id="intref0440">GSE33658</ext-link> dataset (<xref rid="bib43" ref-type="bibr">Massarweh et&#x000a0;al., 2011</xref>). SLC1A2 and AURKA log2 normalized expression levels were reported. Changes were obtained by subtracting from the expression value of tumor that have been treated with fulvestrant that of baseline expression. Correlation analysis was performed using Spearman correlation test.</p></sec></sec><sec id="sec4.5"><title>Quantitation and Statistical Analysis</title><p id="p0265">Statistics were performed using GraphPad Prism 8. Unless stated otherwise, all numerical data are expressed as the mean &#x000b1; error of the mean (SEM) and noted in figure legends. Unless stated otherwise, comparisons between 2 groups were made using the two-tailed, unpaired Student&#x02019;s t test. Comparisons between multiple groups were made using one-way analysis of variance (ANOVA), and two-way ANOVA for comparisons between multiple groups with independent variables. Bonferroni post-testing (unless otherwise stated) with a confidence interval of 95% was used for individual comparisons. Multivariate Cox Analyses on the cohort of patients analyzed in <xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>G and 7H were generated using KM-plotter and are reported in <xref rid="mmc1" ref-type="supplementary-material">Table S3</xref>. Statistical significance was defined as: <sup>&#x02217;</sup>, p&#x000a0;&#x0003c; 0.05; <sup>&#x02217;&#x02217;</sup>, p&#x000a0;&#x0003c; 0.01; <sup>&#x02217;&#x02217;&#x02217;</sup>, p&#x000a0;&#x0003c; 0.001; ns, not significant.</p></sec><sec sec-type="data-availability" id="sec4.6"><title>Data and Code Availability</title><p id="p0270">mRNA and miRNA data derived from microarray analysis are deposited in NCBI Gene Expression Omnibus (GEO) database: accession number <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE120931" id="intref0445">GSE120931</ext-link>. Feature Extraction 10.7.3.1 software (Agilent Technologies) was used to obtain the microarray raw-data and data.</p><p id="p0275">The R script (mM_Net.R) for the interactor network analysis displayed in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C is available and can be downloaded (<ext-link ext-link-type="uri" xlink:href="https://github.com/matteoramazzotti/TransTools" id="intref0450">https://github.com/matteoramazzotti/TransTools</ext-link>).</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>An</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Nie</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name></person-group><article-title>miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2</article-title><source>Cell Death Dis.</source><volume>6</volume><year>2015</year><fpage>e1766</fpage><pub-id pub-id-type="pmid">25996293</pub-id></element-citation><mixed-citation id="srct0045">An, Y., Zhang, Z., Shang, Y., Jiang, X., Dong, J., Yu, P., Nie, Y., and Zhao, Q. (2015). miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 6, e1766.</mixed-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Babu</surname><given-names>E.</given-names></name><name><surname>Bhutia</surname><given-names>Y.D.</given-names></name><name><surname>Ramachandran</surname><given-names>S.</given-names></name><name><surname>Gnanaprakasam</surname><given-names>J.P.</given-names></name><name><surname>Prasad</surname><given-names>P.D.</given-names></name><name><surname>Thangaraju</surname><given-names>M.</given-names></name><name><surname>Ganapathy</surname><given-names>V.</given-names></name></person-group><article-title>Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer</article-title><source>Biochem. J.</source><volume>469</volume><year>2015</year><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">26173258</pub-id></element-citation><mixed-citation id="srct0050">Babu, E., Bhutia, Y.D., Ramachandran, S., Gnanaprakasam, J.P., Prasad, P.D., Thangaraju, M., and Ganapathy, V. (2015). Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer. Biochem. J. 469, 17-23.</mixed-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>M.</given-names></name><name><surname>Giannoni</surname><given-names>E.</given-names></name><name><surname>Fearns</surname><given-names>A.</given-names></name><name><surname>Ribas</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>Q.</given-names></name><name><surname>Taddei</surname><given-names>M.L.</given-names></name><name><surname>Pintus</surname><given-names>G.</given-names></name><name><surname>Dowsett</surname><given-names>M.</given-names></name><name><surname>Isacke</surname><given-names>C.M.</given-names></name><name><surname>Martin</surname><given-names>L.A.</given-names></name></person-group><article-title>miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors</article-title><source>Cancer Res.</source><volume>76</volume><year>2016</year><fpage>1615</fpage><lpage>1626</lpage><pub-id pub-id-type="pmid">26795347</pub-id></element-citation><mixed-citation id="srct0055">Bacci, M., Giannoni, E., Fearns, A., Ribas, R., Gao, Q., Taddei, M.L., Pintus, G., Dowsett, M., Isacke, C.M., Martin, L.A., et&#x000a0;al. (2016). miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res. 76, 1615-1626.</mixed-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Begum</surname><given-names>S.</given-names></name><name><surname>Hayashi</surname><given-names>M.</given-names></name><name><surname>Ogawa</surname><given-names>T.</given-names></name><name><surname>Jabboure</surname><given-names>F.J.</given-names></name><name><surname>Brait</surname><given-names>M.</given-names></name><name><surname>Izumchenko</surname><given-names>E.</given-names></name><name><surname>Tabak</surname><given-names>S.</given-names></name><name><surname>Ahrendt</surname><given-names>S.A.</given-names></name><name><surname>Westra</surname><given-names>W.H.</given-names></name><name><surname>Koch</surname><given-names>W.</given-names></name></person-group><article-title>An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: clinical significance of miR-23b-3p deregulation</article-title><source>Sci. Rep.</source><volume>5</volume><year>2015</year><fpage>13236</fpage><pub-id pub-id-type="pmid">26314549</pub-id></element-citation><mixed-citation id="srct0060">Begum, S., Hayashi, M., Ogawa, T., Jabboure, F.J., Brait, M., Izumchenko, E., Tabak, S., Ahrendt, S.A., Westra, W.H., Koch, W., et&#x000a0;al. (2015). An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: clinical significance of miR-23b-3p deregulation. Sci. Rep. 5, 13236.</mixed-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Bisognin</surname><given-names>A.</given-names></name><name><surname>Sales</surname><given-names>G.</given-names></name><name><surname>Coppe</surname><given-names>A.</given-names></name><name><surname>Bortoluzzi</surname><given-names>S.</given-names></name><name><surname>Romualdi</surname><given-names>C.</given-names></name></person-group><article-title>MAGIA2: from miRNA and genes expression data integrative analysis to microRNA-transcription factor mixed regulatory circuits (2012 update)</article-title><source>Nucleic Acids Res.</source><volume>40</volume><issue>Web Server issue</issue><year>2012</year><fpage>W13</fpage><lpage>W21</lpage><pub-id pub-id-type="pmid">22618880</pub-id></element-citation><mixed-citation id="srct0065">Bisognin, A., Sales, G., Coppe, A., Bortoluzzi, S., and Romualdi, C. (2012). MAGIA2: from miRNA and genes expression data integrative analysis to microRNA-transcription factor mixed regulatory circuits (2012 update). Nucleic Acids Res. 40(Web Server issue), W13-W21.</mixed-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Budczies</surname><given-names>J.</given-names></name><name><surname>Klauschen</surname><given-names>F.</given-names></name><name><surname>Sinn</surname><given-names>B.V.</given-names></name><name><surname>Gy&#x00151;rffy</surname><given-names>B.</given-names></name><name><surname>Schmitt</surname><given-names>W.D.</given-names></name><name><surname>Darb-Esfahani</surname><given-names>S.</given-names></name><name><surname>Denkert</surname><given-names>C.</given-names></name></person-group><article-title>Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e51862</fpage><pub-id pub-id-type="pmid">23251644</pub-id></element-citation><mixed-citation id="srct0070">Budczies, J., Klauschen, F., Sinn, B.V., Gy&#x00151;rffy, B., Schmitt, W.D., Darb-Esfahani, S., and Denkert, C. (2012). Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 7, e51862.</mixed-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Xia</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Zhan</surname><given-names>Q.</given-names></name><name><surname>An</surname><given-names>F.</given-names></name></person-group><article-title>Upregulated exosomic miR-23b-3p plays regulatory roles in the progression of pancreatic cancer</article-title><source>Oncol. Rep.</source><volume>38</volume><year>2017</year><fpage>2182</fpage><lpage>2188</lpage><pub-id pub-id-type="pmid">28849236</pub-id></element-citation><mixed-citation id="srct0075">Chen, D., Wu, X., Xia, M., Wu, F., Ding, J., Jiao, Y., Zhan, Q., and An, F. (2017). Upregulated exosomic miR-23b-3p plays regulatory roles in the progression of pancreatic cancer. Oncol. Rep. 38, 2182-2188.</mixed-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Jang</surname><given-names>I.</given-names></name><name><surname>Jun</surname><given-names>Y.</given-names></name><name><surname>Yoon</surname><given-names>S.</given-names></name><name><surname>Ko</surname><given-names>M.</given-names></name><name><surname>Kwon</surname><given-names>Y.</given-names></name><name><surname>Choi</surname><given-names>I.</given-names></name><name><surname>Chang</surname><given-names>H.</given-names></name><name><surname>Ryu</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name></person-group><article-title>MiRGator v3.0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting</article-title><source>Nucleic Acids Res.</source><volume>41</volume><year>2013</year><fpage>D252</fpage><lpage>D257</lpage><pub-id pub-id-type="pmid">23193297</pub-id></element-citation><mixed-citation id="srct0080">Cho, S., Jang, I., Jun, Y., Yoon, S., Ko, M., Kwon, Y., Choi, I., Chang, H., Ryu, D., Lee, B., et&#x000a0;al. (2013). MiRGator v3.0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res. 41, D252-D257.</mixed-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>C.H.</given-names></name><name><surname>Shrestha</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>C.D.</given-names></name><name><surname>Chang</surname><given-names>N.W.</given-names></name><name><surname>Lin</surname><given-names>Y.L.</given-names></name><name><surname>Liao</surname><given-names>K.W.</given-names></name><name><surname>Huang</surname><given-names>W.C.</given-names></name><name><surname>Sun</surname><given-names>T.H.</given-names></name><name><surname>Tu</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>W.H.</given-names></name></person-group><article-title>miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions</article-title><source>Nucleic Acids Res.</source><volume>46</volume><issue>D1</issue><year>2018</year><fpage>D296</fpage><lpage>D302</lpage><pub-id pub-id-type="pmid">29126174</pub-id></element-citation><mixed-citation id="srct0085">Chou, C.H., Shrestha, S., Yang, C.D., Chang, N.W., Lin, Y.L., Liao, K.W., Huang, W.C., Sun, T.H., Tu, S.J., Lee, W.H., et&#x000a0;al. (2018). miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 46 (D1), D296-D302.</mixed-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>C.</given-names></name><name><surname>Madden</surname><given-names>S.F.</given-names></name><name><surname>Doolan</surname><given-names>P.</given-names></name><name><surname>Aherne</surname><given-names>S.T.</given-names></name><name><surname>Joyce</surname><given-names>H.</given-names></name><name><surname>O&#x02019;Driscoll</surname><given-names>L.</given-names></name><name><surname>Gallagher</surname><given-names>W.M.</given-names></name><name><surname>Hennessy</surname><given-names>B.T.</given-names></name><name><surname>Moriarty</surname><given-names>M.</given-names></name><name><surname>Crown</surname><given-names>J.</given-names></name></person-group><article-title>Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis</article-title><source>Carcinogenesis</source><volume>34</volume><year>2013</year><fpage>2300</fpage><lpage>2308</lpage><pub-id pub-id-type="pmid">23740839</pub-id></element-citation><mixed-citation id="srct0090">Clarke, C., Madden, S.F., Doolan, P., Aherne, S.T., Joyce, H., O&#x02019;Driscoll, L., Gallagher, W.M., Hennessy, B.T., Moriarty, M., Crown, J., et&#x000a0;al. (2013). Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 34, 2300-2308.</mixed-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>K.L.</given-names></name><name><surname>Shajahan</surname><given-names>A.N.</given-names></name><name><surname>Clarke</surname><given-names>R.</given-names></name></person-group><article-title>Autophagy and endocrine resistance in breast cancer</article-title><source>Expert Rev. Anticancer Ther.</source><volume>11</volume><year>2011</year><fpage>1283</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">21916582</pub-id></element-citation><mixed-citation id="srct0095">Cook, K.L., Shajahan, A.N., and Clarke, R. (2011). Autophagy and endocrine resistance in breast cancer. Expert Rev. Anticancer Ther. 11, 1283-1294.</mixed-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Coothankandaswamy</surname><given-names>V.</given-names></name><name><surname>Cao</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Prasad</surname><given-names>P.D.</given-names></name><name><surname>Singh</surname><given-names>P.K.</given-names></name><name><surname>Reynolds</surname><given-names>C.P.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Ogura</surname><given-names>J.</given-names></name><name><surname>Ganapathy</surname><given-names>V.</given-names></name><name><surname>Bhutia</surname><given-names>Y.D.</given-names></name></person-group><article-title>Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer</article-title><source>Br. J. Pharmacol.</source><volume>173</volume><year>2016</year><fpage>3292</fpage><lpage>3306</lpage><pub-id pub-id-type="pmid">27747870</pub-id></element-citation><mixed-citation id="srct0100">Coothankandaswamy, V., Cao, S., Xu, Y., Prasad, P.D., Singh, P.K., Reynolds, C.P., Yang, S., Ogura, J., Ganapathy, V., and Bhutia, Y.D. (2016). Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br. J. Pharmacol. 173, 3292-3306.</mixed-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Cottu</surname><given-names>P.</given-names></name><name><surname>Bi&#x000e8;che</surname><given-names>I.</given-names></name><name><surname>Assayag</surname><given-names>F.</given-names></name><name><surname>El Botty</surname><given-names>R.</given-names></name><name><surname>Chateau-Joubert</surname><given-names>S.</given-names></name><name><surname>Thuleau</surname><given-names>A.</given-names></name><name><surname>Bagarre</surname><given-names>T.</given-names></name><name><surname>Albaud</surname><given-names>B.</given-names></name><name><surname>Rapinat</surname><given-names>A.</given-names></name><name><surname>Gentien</surname><given-names>D.</given-names></name></person-group><article-title>Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts</article-title><source>Clin. Cancer Res.</source><volume>20</volume><year>2014</year><fpage>4314</fpage><lpage>4325</lpage><pub-id pub-id-type="pmid">24947930</pub-id></element-citation><mixed-citation id="srct0105">Cottu, P., Bieche, I., Assayag, F., El Botty, R., Chateau-Joubert, S., Thuleau, A., Bagarre, T., Albaud, B., Rapinat, A., Gentien, D., et&#x000a0;al. (2014). Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Clin. Cancer Res. 20, 4314-4325.</mixed-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Dedeurwaerder</surname><given-names>S.</given-names></name><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Calonne</surname><given-names>E.</given-names></name><name><surname>Singhal</surname><given-names>S.K.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><name><surname>Defrance</surname><given-names>M.</given-names></name><name><surname>Michiels</surname><given-names>S.</given-names></name><name><surname>Volkmar</surname><given-names>M.</given-names></name><name><surname>Deplus</surname><given-names>R.</given-names></name><name><surname>Luciani</surname><given-names>J.</given-names></name></person-group><article-title>DNA methylation profiling reveals a predominant immune component in breast cancers</article-title><source>EMBO Mol. Med.</source><volume>3</volume><year>2011</year><fpage>726</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">21910250</pub-id></element-citation><mixed-citation id="srct0110">Dedeurwaerder, S., Desmedt, C., Calonne, E., Singhal, S.K., Haibe-Kains, B., Defrance, M., Michiels, S., Volkmar, M., Deplus, R., Luciani, J., et&#x000a0;al. (2011). DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol. Med. 3, 726-741.</mixed-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Piette</surname><given-names>F.</given-names></name><name><surname>Loi</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Lallemand</surname><given-names>F.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><name><surname>Viale</surname><given-names>G.</given-names></name><name><surname>Delorenzi</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>d&#x02019;Assignies</surname><given-names>M.S.</given-names></name><collab>TRANSBIG Consortium</collab></person-group><article-title>Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series</article-title><source>Clin. Cancer Res.</source><volume>13</volume><year>2007</year><fpage>3207</fpage><lpage>3214</lpage><pub-id pub-id-type="pmid">17545524</pub-id></element-citation><mixed-citation id="srct0115">Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d&#x02019;Assignies, M.S., et&#x000a0;al.; TRANSBIG Consortium (2007). Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13, 3207-3214.</mixed-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><name><surname>Neven</surname><given-names>P.</given-names></name><name><surname>Paridaens</surname><given-names>R.</given-names></name><name><surname>Christiaens</surname><given-names>M.R.</given-names></name><name><surname>Smeets</surname><given-names>A.</given-names></name><name><surname>Lallemand</surname><given-names>F.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><name><surname>Viale</surname><given-names>G.</given-names></name><name><surname>Gelber</surname><given-names>R.D.</given-names></name></person-group><article-title>The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial</article-title><source>BMC Med. Genomics</source><volume>2</volume><year>2009</year><fpage>40</fpage><pub-id pub-id-type="pmid">19573224</pub-id></element-citation><mixed-citation id="srct0120">Desmedt, C., Giobbie-Hurder, A., Neven, P., Paridaens, R., Christiaens, M.R., Smeets, A., Lallemand, F., Haibe-Kains, B., Viale, G., Gelber, R.D., et&#x000a0;al. (2009). The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med. Genomics 2, 40.</mixed-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Dumortier</surname><given-names>O.</given-names></name><name><surname>Hinault</surname><given-names>C.</given-names></name><name><surname>Van Obberghen</surname><given-names>E.</given-names></name></person-group><article-title>MicroRNAs and metabolism crosstalk in energy homeostasis</article-title><source>Cell Metab.</source><volume>18</volume><year>2013</year><fpage>312</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">23850315</pub-id></element-citation><mixed-citation id="srct0125">Dumortier, O., Hinault, C., and Van Obberghen, E. (2013). MicroRNAs and metabolism crosstalk in energy homeostasis. Cell Metab. 18, 312-324.</mixed-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Ferracin</surname><given-names>M.</given-names></name><name><surname>Bassi</surname><given-names>C.</given-names></name><name><surname>Pedriali</surname><given-names>M.</given-names></name><name><surname>Pagotto</surname><given-names>S.</given-names></name><name><surname>D&#x02019;Abundo</surname><given-names>L.</given-names></name><name><surname>Zagatti</surname><given-names>B.</given-names></name><name><surname>Corr&#x000e0;</surname><given-names>F.</given-names></name><name><surname>Musa</surname><given-names>G.</given-names></name><name><surname>Callegari</surname><given-names>E.</given-names></name><name><surname>Lupini</surname><given-names>L.</given-names></name></person-group><article-title>miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression</article-title><source>Mol. Cancer</source><volume>12</volume><year>2013</year><fpage>130</fpage><pub-id pub-id-type="pmid">24165569</pub-id></element-citation><mixed-citation id="srct0130">Ferracin, M., Bassi, C., Pedriali, M., Pagotto, S., D&#x02019;Abundo, L., Zagatti, B., Corra, F., Musa, G., Callegari, E., Lupini, L., et&#x000a0;al. (2013). miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol. Cancer 12, 130.</mixed-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Filipits</surname><given-names>M.</given-names></name><name><surname>Rudas</surname><given-names>M.</given-names></name><name><surname>Jakesz</surname><given-names>R.</given-names></name><name><surname>Dubsky</surname><given-names>P.</given-names></name><name><surname>Fitzal</surname><given-names>F.</given-names></name><name><surname>Singer</surname><given-names>C.F.</given-names></name><name><surname>Dietze</surname><given-names>O.</given-names></name><name><surname>Greil</surname><given-names>R.</given-names></name><name><surname>Jelen</surname><given-names>A.</given-names></name><name><surname>Sevelda</surname><given-names>P.</given-names></name><collab>EP Investigators</collab></person-group><article-title>A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors</article-title><source>Clin. Cancer Res.</source><volume>17</volume><year>2011</year><fpage>6012</fpage><lpage>6020</lpage><pub-id pub-id-type="pmid">21807638</pub-id></element-citation><mixed-citation id="srct0135">Filipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C.F., Dietze, O., Greil, R., Jelen, A., Sevelda, P., et&#x000a0;al.; EP Investigators (2011). A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17, 6012-6020.</mixed-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>J.F.</given-names></name><name><surname>Cuzick</surname><given-names>J.</given-names></name><name><surname>Buzdar</surname><given-names>A.</given-names></name><name><surname>Howell</surname><given-names>A.</given-names></name><name><surname>Tobias</surname><given-names>J.S.</given-names></name><name><surname>Baum</surname><given-names>M.</given-names></name><collab>Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists&#x02019; Group</collab></person-group><article-title>Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial</article-title><source>Lancet Oncol.</source><volume>9</volume><year>2008</year><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18083636</pub-id></element-citation><mixed-citation id="srct0140">Forbes, J.F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J.S., Baum, M.; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists&#x02019; Group (2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45-53.</mixed-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>E.M.</given-names></name><name><surname>Kuba</surname><given-names>M.G.</given-names></name><name><surname>Miller</surname><given-names>T.W.</given-names></name><name><surname>Davies</surname><given-names>B.R.</given-names></name><name><surname>Arteaga</surname><given-names>C.L.</given-names></name></person-group><article-title>Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation</article-title><source>Breast Cancer Res.</source><volume>15</volume><year>2013</year><fpage>R55</fpage><pub-id pub-id-type="pmid">23844554</pub-id></element-citation><mixed-citation id="srct0145">Fox, E.M., Kuba, M.G., Miller, T.W., Davies, B.R., and Arteaga, C.L. (2013). Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res. 15, R55.</mixed-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Fulciniti</surname><given-names>M.</given-names></name><name><surname>Amodio</surname><given-names>N.</given-names></name><name><surname>Bandi</surname><given-names>R.L.</given-names></name><name><surname>Cagnetta</surname><given-names>A.</given-names></name><name><surname>Samur</surname><given-names>M.K.</given-names></name><name><surname>Acharya</surname><given-names>C.</given-names></name><name><surname>Prabhala</surname><given-names>R.</given-names></name><name><surname>D&#x02019;Aquila</surname><given-names>P.</given-names></name><name><surname>Bellizzi</surname><given-names>D.</given-names></name><name><surname>Passarino</surname><given-names>G.</given-names></name></person-group><article-title>miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth</article-title><source>Blood Cancer J.</source><volume>6</volume><year>2016</year><fpage>e380</fpage><pub-id pub-id-type="pmid">26771806</pub-id></element-citation><mixed-citation id="srct0150">Fulciniti, M., Amodio, N., Bandi, R.L., Cagnetta, A., Samur, M.K., Acharya, C., Prabhala, R., D&#x02019;Aquila, P., Bellizzi, D., Passarino, G., et&#x000a0;al. (2016). miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 6, e380.</mixed-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L.</given-names></name><name><surname>Pietrocola</surname><given-names>F.</given-names></name><name><surname>Levine</surname><given-names>B.</given-names></name><name><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Metabolic control of autophagy</article-title><source>Cell</source><volume>159</volume><year>2014</year><fpage>1263</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">25480292</pub-id></element-citation><mixed-citation id="srct0155">Galluzzi, L., Pietrocola, F., Levine, B., and Kroemer, G. (2014). Metabolic control of autophagy. Cell 159, 1263-1276.</mixed-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Galluzzi</surname><given-names>L.</given-names></name><name><surname>Pietrocola</surname><given-names>F.</given-names></name><name><surname>Bravo-San Pedro</surname><given-names>J.M.</given-names></name><name><surname>Amaravadi</surname><given-names>R.K.</given-names></name><name><surname>Baehrecke</surname><given-names>E.H.</given-names></name><name><surname>Cecconi</surname><given-names>F.</given-names></name><name><surname>Codogno</surname><given-names>P.</given-names></name><name><surname>Debnath</surname><given-names>J.</given-names></name><name><surname>Gewirtz</surname><given-names>D.A.</given-names></name><name><surname>Karantza</surname><given-names>V.</given-names></name></person-group><article-title>Autophagy in malignant transformation and cancer progression</article-title><source>EMBO J.</source><volume>34</volume><year>2015</year><fpage>856</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">25712477</pub-id></element-citation><mixed-citation id="srct0160">Galluzzi, L., Pietrocola, F., Bravo-San Pedro, J.M., Amaravadi, R.K., Baehrecke, E.H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D.A., Karantza, V., et&#x000a0;al. (2015). Autophagy in malignant transformation and cancer progression. EMBO J. 34, 856-880.</mixed-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Garcia-Bermudez</surname><given-names>J.</given-names></name><name><surname>Baudrier</surname><given-names>L.</given-names></name><name><surname>La</surname><given-names>K.</given-names></name><name><surname>Zhu</surname><given-names>X.G.</given-names></name><name><surname>Fidelin</surname><given-names>J.</given-names></name><name><surname>Sviderskiy</surname><given-names>V.O.</given-names></name><name><surname>Papagiannakopoulos</surname><given-names>T.</given-names></name><name><surname>Molina</surname><given-names>H.</given-names></name><name><surname>Snuderl</surname><given-names>M.</given-names></name><name><surname>Lewis</surname><given-names>C.A.</given-names></name></person-group><article-title>Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours</article-title><source>Nat. Cell Biol.</source><volume>20</volume><year>2018</year><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">29941933</pub-id></element-citation><mixed-citation id="srct0165">Garcia-Bermudez, J., Baudrier, L., La, K., Zhu, X.G., Fidelin, J., Sviderskiy, V.O., Papagiannakopoulos, T., Molina, H., Snuderl, M., Lewis, C.A., et&#x000a0;al. (2018). Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 20, 775-781.</mixed-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Gozuacik</surname><given-names>D.</given-names></name><name><surname>Akkoc</surname><given-names>Y.</given-names></name><name><surname>Ozturk</surname><given-names>D.G.</given-names></name><name><surname>Kocak</surname><given-names>M.</given-names></name></person-group><article-title>Autophagy-Regulating microRNAs and Cancer</article-title><source>Front. Oncol.</source><volume>7</volume><year>2017</year><fpage>65</fpage><pub-id pub-id-type="pmid">28459042</pub-id></element-citation><mixed-citation id="srct0170">Gozuacik, D., Akkoc, Y., Ozturk, D.G., and Kocak, M. (2017). Autophagy-Regulating microRNAs and Cancer. Front. Oncol. 7, 65.</mixed-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>D.Y.</given-names></name><name><surname>Sullivan</surname><given-names>L.B.</given-names></name><name><surname>Luengo</surname><given-names>A.</given-names></name><name><surname>Hosios</surname><given-names>A.M.</given-names></name><name><surname>Bush</surname><given-names>L.N.</given-names></name><name><surname>Gitego</surname><given-names>N.</given-names></name><name><surname>Davidson</surname><given-names>S.M.</given-names></name><name><surname>Freinkman</surname><given-names>E.</given-names></name><name><surname>Thomas</surname><given-names>C.J.</given-names></name><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin</article-title><source>Cell Metab.</source><volume>24</volume><year>2016</year><fpage>716</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">27746050</pub-id></element-citation><mixed-citation id="srct0175">Gui, D.Y., Sullivan, L.B., Luengo, A., Hosios, A.M., Bush, L.N., Gitego, N., Davidson, S.M., Freinkman, E., Thomas, C.J., and Vander Heiden, M.G. (2016). Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. Cell Metab. 24, 716-727.</mixed-citation></ref><ref id="bib79"><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Gy&#x000f6;rffy</surname><given-names>B.</given-names></name><name><surname>Lanczky</surname><given-names>A.</given-names></name><name><surname>Eklund</surname><given-names>A.C.</given-names></name><name><surname>Denkert</surname><given-names>C.</given-names></name><name><surname>Budczies</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Szallasi</surname><given-names>Z.</given-names></name></person-group><article-title>An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients</article-title><source>Breast Cancer Res. Treat.</source><volume>123</volume><year>2010</year><fpage>725</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">20020197</pub-id></element-citation><mixed-citation id="srct0435">Gy&#x000f6;rffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.Breast Cancer Res Treat. 123, 725-31.</mixed-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Hediger</surname><given-names>M.A.</given-names></name><name><surname>Romero</surname><given-names>M.F.</given-names></name><name><surname>Peng</surname><given-names>J.B.</given-names></name><name><surname>Rolfs</surname><given-names>A.</given-names></name><name><surname>Takanaga</surname><given-names>H.</given-names></name><name><surname>Bruford</surname><given-names>E.A.</given-names></name></person-group><article-title>The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction</article-title><source>Pflugers Arch.</source><volume>447</volume><year>2004</year><fpage>465</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">14624363</pub-id></element-citation><mixed-citation id="srct0180">Hediger, M.A., Romero, M.F., Peng, J.B., Rolfs, A., Takanaga, H., and Bruford, E.A. (2004). The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch. 447, 465-468.</mixed-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Hosios</surname><given-names>A.M.</given-names></name><name><surname>Hecht</surname><given-names>V.C.</given-names></name><name><surname>Danai</surname><given-names>L.V.</given-names></name><name><surname>Johnson</surname><given-names>M.O.</given-names></name><name><surname>Rathmell</surname><given-names>J.C.</given-names></name><name><surname>Steinhauser</surname><given-names>M.L.</given-names></name><name><surname>Manalis</surname><given-names>S.R.</given-names></name><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells</article-title><source>Dev. Cell</source><volume>36</volume><year>2016</year><fpage>540</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">26954548</pub-id></element-citation><mixed-citation id="srct0185">Hosios, A.M., Hecht, V.C., Danai, L.V., Johnson, M.O., Rathmell, J.C., Steinhauser, M.L., Manalis, S.R., and Vander Heiden, M.G. (2016). Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. Dev. Cell 36, 540-549.</mixed-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Karn</surname><given-names>T.</given-names></name><name><surname>Metzler</surname><given-names>D.</given-names></name><name><surname>Ruckh&#x000e4;berle</surname><given-names>E.</given-names></name><name><surname>Hanker</surname><given-names>L.</given-names></name><name><surname>G&#x000e4;tje</surname><given-names>R.</given-names></name><name><surname>Solbach</surname><given-names>C.</given-names></name><name><surname>Ahr</surname><given-names>A.</given-names></name><name><surname>Schmidt</surname><given-names>M.</given-names></name><name><surname>Holtrich</surname><given-names>U.</given-names></name><name><surname>Kaufmann</surname><given-names>M.</given-names></name><name><surname>Rody</surname><given-names>A.</given-names></name></person-group><article-title>Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer</article-title><source>Breast Cancer Res. Treat.</source><volume>120</volume><year>2010</year><fpage>567</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">19455418</pub-id></element-citation><mixed-citation id="srct0190">Karn, T., Metzler, D., Ruckhaberle, E., Hanker, L., Gatje, R., Solbach, C., Ahr, A., Schmidt, M., Holtrich, U., Kaufmann, M., and Rody, A. (2010). Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res. Treat. 120, 567-579.</mixed-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Karunakaran</surname><given-names>S.</given-names></name><name><surname>Ramachandran</surname><given-names>S.</given-names></name><name><surname>Coothankandaswamy</surname><given-names>V.</given-names></name><name><surname>Elangovan</surname><given-names>S.</given-names></name><name><surname>Babu</surname><given-names>E.</given-names></name><name><surname>Periyasamy-Thandavan</surname><given-names>S.</given-names></name><name><surname>Gurav</surname><given-names>A.</given-names></name><name><surname>Gnanaprakasam</surname><given-names>J.P.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Schoenlein</surname><given-names>P.V.</given-names></name></person-group><article-title>SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>286</volume><year>2011</year><fpage>31830</fpage><lpage>31838</lpage><pub-id pub-id-type="pmid">21771784</pub-id></element-citation><mixed-citation id="srct0195">Karunakaran, S., Ramachandran, S., Coothankandaswamy, V., Elangovan, S., Babu, E., Periyasamy-Thandavan, S., Gurav, A., Gnanaprakasam, J.P., Singh, N., Schoenlein, P.V., et&#x000a0;al. (2011). SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J. Biol. Chem. 286, 31830-31838.</mixed-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Kertesz</surname><given-names>M.</given-names></name><name><surname>Iovino</surname><given-names>N.</given-names></name><name><surname>Unnerstall</surname><given-names>U.</given-names></name><name><surname>Gaul</surname><given-names>U.</given-names></name><name><surname>Segal</surname><given-names>E.</given-names></name></person-group><article-title>The role of site accessibility in microRNA target recognition</article-title><source>Nat. Genet.</source><volume>39</volume><year>2007</year><fpage>1278</fpage><lpage>1284</lpage><pub-id pub-id-type="pmid">17893677</pub-id></element-citation><mixed-citation id="srct0200">Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of site accessibility in microRNA target recognition. Nat. Genet. 39, 1278-1284.</mixed-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Kishore</surname><given-names>S.</given-names></name><name><surname>Jaskiewicz</surname><given-names>L.</given-names></name><name><surname>Burger</surname><given-names>L.</given-names></name><name><surname>Hausser</surname><given-names>J.</given-names></name><name><surname>Khorshid</surname><given-names>M.</given-names></name><name><surname>Zavolan</surname><given-names>M.</given-names></name></person-group><article-title>A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins</article-title><source>Nat. Methods</source><volume>8</volume><year>2011</year><fpage>559</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">21572407</pub-id></element-citation><mixed-citation id="srct0205">Kishore, S., Jaskiewicz, L., Burger, L., Hausser, J., Khorshid, M., and Zavolan, M. (2011). A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat. Methods 8, 559-564..</mixed-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>L&#x000e1;nczky</surname><given-names>A.</given-names></name><name><surname>Nagy</surname><given-names>&#x000c1;.</given-names></name><name><surname>Bottai</surname><given-names>G.</given-names></name><name><surname>Munk&#x000e1;csy</surname><given-names>G.</given-names></name><name><surname>Szab&#x000f3;</surname><given-names>A.</given-names></name><name><surname>Santarpia</surname><given-names>L.</given-names></name><name><surname>Gy&#x00151;rffy</surname><given-names>B.</given-names></name></person-group><article-title>miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients</article-title><source>Breast Cancer Res. Treat.</source><volume>160</volume><year>2016</year><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">27744485</pub-id></element-citation><mixed-citation id="srct0210">Lanczky, A., Nagy, A., Bottai, G., Munkacsy, G., Szabo, A., Santarpia, L., and Gy&#x00151;rffy, B. (2016). miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res. Treat. 160, 439-446.</mixed-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><name><surname>Tian</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Sotiriou</surname><given-names>C.</given-names></name><name><surname>Szallasi</surname><given-names>Z.</given-names></name><name><surname>Iglehart</surname><given-names>J.D.</given-names></name></person-group><article-title>Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer</article-title><source>Nat. Med.</source><volume>16</volume><year>2010</year><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">20098429</pub-id></element-citation><mixed-citation id="srct0215">Li, Y., Zou, L., Li, Q., Haibe-Kains, B., Tian, R., Li, Y., Desmedt, C., Sotiriou, C., Szallasi, Z., Iglehart, J.D., et&#x000a0;al. (2010). Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat. Med. 16, 214-218.</mixed-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name></person-group><article-title>Up-regulated expression of miR-23a/b targeted the pro-apoptotic Fas in radiation-induced thymic lymphoma</article-title><source>Cell. Physiol. Biochem.</source><volume>32</volume><year>2013</year><fpage>1729</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">24356489</pub-id></element-citation><mixed-citation id="srct0220">Li, B., Sun, M., Gao, F., Liu, W., Yang, Y., Liu, H., Cheng, Y., Liu, C., and Cai, J. (2013). Up-regulated expression of miR-23a/b targeted the pro-apoptotic Fas in radiation-induced thymic lymphoma. Cell. Physiol. Biochem. 32, 1729-1740.</mixed-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Stoleru</surname><given-names>D.</given-names></name><name><surname>Salic</surname><given-names>A.</given-names></name></person-group><article-title>Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>109</volume><year>2012</year><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">22160674</pub-id></element-citation><mixed-citation id="srct0225">Liu, J., Xu, Y., Stoleru, D., and Salic, A. (2012). Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc. Natl. Acad. Sci. USA 109, 413-418.</mixed-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Miller</surname><given-names>T.</given-names></name><name><surname>Murph</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Gagea</surname><given-names>M.</given-names></name><name><surname>Arteaga</surname><given-names>C.L.</given-names></name></person-group><article-title>Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer</article-title><source>Oncotarget</source><volume>5</volume><year>2014</year><fpage>9049</fpage><lpage>9064</lpage><pub-id pub-id-type="pmid">24979294</pub-id></element-citation><mixed-citation id="srct0230">Liu, S., Meng, X., Chen, H., Liu, W., Miller, T., Murph, M., Lu, Y., Zhang, F., Gagea, M., Arteaga, C.L., et&#x000a0;al. (2014). Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget 5, 9049-9064.</mixed-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Loi</surname><given-names>S.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Lallemand</surname><given-names>F.</given-names></name><name><surname>Tutt</surname><given-names>A.M.</given-names></name><name><surname>Gillet</surname><given-names>C.</given-names></name><name><surname>Ellis</surname><given-names>P.</given-names></name><name><surname>Harris</surname><given-names>A.</given-names></name><name><surname>Bergh</surname><given-names>J.</given-names></name><name><surname>Foekens</surname><given-names>J.A.</given-names></name></person-group><article-title>Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade</article-title><source>J.&#x000a0;Clin. Oncol.</source><volume>25</volume><year>2007</year><fpage>1239</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">17401012</pub-id></element-citation><mixed-citation id="srct0235">Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A.M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J.A., et&#x000a0;al. (2007). Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25, 1239-1246.</mixed-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Loi</surname><given-names>S.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Wirapati</surname><given-names>P.</given-names></name><name><surname>Lallemand</surname><given-names>F.</given-names></name><name><surname>Tutt</surname><given-names>A.M.</given-names></name><name><surname>Gillet</surname><given-names>C.</given-names></name><name><surname>Ellis</surname><given-names>P.</given-names></name><name><surname>Ryder</surname><given-names>K.</given-names></name><name><surname>Reid</surname><given-names>J.F.</given-names></name></person-group><article-title>Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen</article-title><source>BMC Genomics</source><volume>9</volume><year>2008</year><fpage>239</fpage><pub-id pub-id-type="pmid">18498629</pub-id></element-citation><mixed-citation id="srct0240">Loi, S., Haibe-Kains, B., Desmedt, C., Wirapati, P., Lallemand, F., Tutt, A.M., Gillet, C., Ellis, P., Ryder, K., Reid, J.F., et&#x000a0;al. (2008). Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9, 239.</mixed-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L.A.</given-names></name><name><surname>Farmer</surname><given-names>I.</given-names></name><name><surname>Johnston</surname><given-names>S.R.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name><name><surname>Marshall</surname><given-names>C.</given-names></name><name><surname>Dowsett</surname><given-names>M.</given-names></name></person-group><article-title>Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>278</volume><year>2003</year><fpage>30458</fpage><lpage>30468</lpage><pub-id pub-id-type="pmid">12775708</pub-id></element-citation><mixed-citation id="srct0245">Martin, L.A., Farmer, I., Johnston, S.R., Ali, S., Marshall, C., and Dowsett, M. (2003). Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. 278, 30458-30468.</mixed-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L.A.</given-names></name><name><surname>Pancholi</surname><given-names>S.</given-names></name><name><surname>Farmer</surname><given-names>I.</given-names></name><name><surname>Guest</surname><given-names>S.</given-names></name><name><surname>Ribas</surname><given-names>R.</given-names></name><name><surname>Weigel</surname><given-names>M.T.</given-names></name><name><surname>Thornhill</surname><given-names>A.M.</given-names></name><name><surname>Ghazoui</surname><given-names>Z.</given-names></name><name><surname>A&#x02019;Hern</surname><given-names>R.</given-names></name><name><surname>Evans</surname><given-names>D.B.</given-names></name></person-group><article-title>Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in&#x000a0;vitro and in&#x000a0;vivo</article-title><source>Breast Cancer Res.</source><volume>14</volume><year>2012</year><fpage>R132</fpage><pub-id pub-id-type="pmid">23075476</pub-id></element-citation><mixed-citation id="srct0250">Martin, L.A., Pancholi, S., Farmer, I., Guest, S., Ribas, R., Weigel, M.T., Thornhill, A.M., Ghazoui, Z., A&#x02019;Hern, R., Evans, D.B., et&#x000a0;al. (2012). Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in&#x000a0;vitro and in&#x000a0;vivo. Breast Cancer Res. 14, R132.</mixed-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Massarweh</surname><given-names>S.</given-names></name><name><surname>Tham</surname><given-names>Y.L.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Sexton</surname><given-names>K.</given-names></name><name><surname>Weiss</surname><given-names>H.</given-names></name><name><surname>Tsimelzon</surname><given-names>A.</given-names></name><name><surname>Beyer</surname><given-names>A.</given-names></name><name><surname>Rimawi</surname><given-names>M.</given-names></name><name><surname>Cai</surname><given-names>W.Y.</given-names></name><name><surname>Hilsenbeck</surname><given-names>S.</given-names></name></person-group><article-title>A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer</article-title><source>Breast Cancer Res. Treat.</source><volume>129</volume><year>2011</year><fpage>819</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">21792626</pub-id></element-citation><mixed-citation id="srct0255">Massarweh, S., Tham, Y.L., Huang, J., Sexton, K., Weiss, H., Tsimelzon, A., Beyer, A., Rimawi, M., Cai, W.Y., Hilsenbeck, S., et&#x000a0;al. (2011). A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 129, 819-827.</mixed-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>L.D.</given-names></name><name><surname>Smeds</surname><given-names>J.</given-names></name><name><surname>George</surname><given-names>J.</given-names></name><name><surname>Vega</surname><given-names>V.B.</given-names></name><name><surname>Vergara</surname><given-names>L.</given-names></name><name><surname>Ploner</surname><given-names>A.</given-names></name><name><surname>Pawitan</surname><given-names>Y.</given-names></name><name><surname>Hall</surname><given-names>P.</given-names></name><name><surname>Klaar</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>E.T.</given-names></name><name><surname>Bergh</surname><given-names>J.</given-names></name></person-group><article-title>An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>102</volume><year>2005</year><fpage>13550</fpage><lpage>13555</lpage><pub-id pub-id-type="pmid">16141321</pub-id></element-citation><mixed-citation id="srct0260">Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E.T., and Bergh, J. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 102, 13550-13555.</mixed-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>W.R.</given-names></name><name><surname>Larionov</surname><given-names>A.A.</given-names></name><name><surname>Renshaw</surname><given-names>L.</given-names></name><name><surname>Anderson</surname><given-names>T.J.</given-names></name><name><surname>White</surname><given-names>S.</given-names></name><name><surname>Murray</surname><given-names>J.</given-names></name><name><surname>Murray</surname><given-names>E.</given-names></name><name><surname>Hampton</surname><given-names>G.</given-names></name><name><surname>Walker</surname><given-names>J.R.</given-names></name><name><surname>Ho</surname><given-names>S.</given-names></name></person-group><article-title>Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole</article-title><source>Pharmacogenet. Genomics</source><volume>17</volume><year>2007</year><fpage>813</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">17885619</pub-id></element-citation><mixed-citation id="srct0265">Miller, W.R., Larionov, A.A., Renshaw, L., Anderson, T.J., White, S., Murray, J., Murray, E., Hampton, G., Walker, J.R., Ho, S., et&#x000a0;al. (2007). Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet. Genomics 17, 813-826.</mixed-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Minn</surname><given-names>A.J.</given-names></name><name><surname>Gupta</surname><given-names>G.P.</given-names></name><name><surname>Siegel</surname><given-names>P.M.</given-names></name><name><surname>Bos</surname><given-names>P.D.</given-names></name><name><surname>Shu</surname><given-names>W.</given-names></name><name><surname>Giri</surname><given-names>D.D.</given-names></name><name><surname>Viale</surname><given-names>A.</given-names></name><name><surname>Olshen</surname><given-names>A.B.</given-names></name><name><surname>Gerald</surname><given-names>W.L.</given-names></name><name><surname>Massagu&#x000e9;</surname><given-names>J.</given-names></name></person-group><article-title>Genes that mediate breast cancer metastasis to lung</article-title><source>Nature</source><volume>436</volume><year>2005</year><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">16049480</pub-id></element-citation><mixed-citation id="srct0270">Minn, A.J., Gupta, G.P., Siegel, P.M., Bos, P.D., Shu, W., Giri, D.D., Viale, A., Olshen, A.B., Gerald, W.L., and Massague, J. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524.</mixed-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Morandi</surname><given-names>A.</given-names></name><name><surname>Indraccolo</surname><given-names>S.</given-names></name></person-group><article-title>Linking metabolic reprogramming to therapy resistance in cancer</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><volume>1868</volume><year>2017</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">28065746</pub-id></element-citation><mixed-citation id="srct0275">Morandi, A., and Indraccolo, S.. (2017). Linking metabolic reprogramming to therapy resistance in cancer. Biochim. Biophys. Acta Rev. Cancer 1868, 1-6.</mixed-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Morandi</surname><given-names>A.</given-names></name><name><surname>Martin</surname><given-names>L.A.</given-names></name><name><surname>Gao</surname><given-names>Q.</given-names></name><name><surname>Pancholi</surname><given-names>S.</given-names></name><name><surname>Mackay</surname><given-names>A.</given-names></name><name><surname>Robertson</surname><given-names>D.</given-names></name><name><surname>Zvelebil</surname><given-names>M.</given-names></name><name><surname>Dowsett</surname><given-names>M.</given-names></name><name><surname>Plaza-Menacho</surname><given-names>I.</given-names></name><name><surname>Isacke</surname><given-names>C.M.</given-names></name></person-group><article-title>GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors</article-title><source>Cancer Res.</source><volume>73</volume><year>2013</year><fpage>3783</fpage><lpage>3795</lpage><pub-id pub-id-type="pmid">23650283</pub-id></element-citation><mixed-citation id="srct0280">Morandi, A., Martin, L.A., Gao, Q., Pancholi, S., Mackay, A., Robertson, D., Zvelebil, M., Dowsett, M., Plaza-Menacho, I., and Isacke, C.M. (2013). GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 73, 3783-3795.</mixed-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Murugaesu</surname><given-names>N.</given-names></name><name><surname>Iravani</surname><given-names>M.</given-names></name><name><surname>van Weverwijk</surname><given-names>A.</given-names></name><name><surname>Ivetic</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>D.A.</given-names></name><name><surname>Antonopoulos</surname><given-names>A.</given-names></name><name><surname>Fearns</surname><given-names>A.</given-names></name><name><surname>Jamal-Hanjani</surname><given-names>M.</given-names></name><name><surname>Sims</surname><given-names>D.</given-names></name><name><surname>Fenwick</surname><given-names>K.</given-names></name></person-group><article-title>An in&#x000a0;vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor</article-title><source>Cancer Discov.</source><volume>4</volume><year>2014</year><fpage>304</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">24520024</pub-id></element-citation><mixed-citation id="srct0285">Murugaesu, N., Iravani, M., van Weverwijk, A., Ivetic, A., Johnson, D.A., Antonopoulos, A., Fearns, A., Jamal-Hanjani, M., Sims, D., Fenwick, K., et&#x000a0;al. (2014). An in&#x000a0;vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov. 4, 304-317.</mixed-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Nagalla</surname><given-names>S.</given-names></name><name><surname>Chou</surname><given-names>J.W.</given-names></name><name><surname>Willingham</surname><given-names>M.C.</given-names></name><name><surname>Ruiz</surname><given-names>J.</given-names></name><name><surname>Vaughn</surname><given-names>J.P.</given-names></name><name><surname>Dubey</surname><given-names>P.</given-names></name><name><surname>Lash</surname><given-names>T.L.</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S.J.</given-names></name><name><surname>Bergh</surname><given-names>J.</given-names></name><name><surname>Sotiriou</surname><given-names>C.</given-names></name></person-group><article-title>Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis</article-title><source>Genome Biol.</source><volume>14</volume><year>2013</year><fpage>R34</fpage><pub-id pub-id-type="pmid">23618380</pub-id></element-citation><mixed-citation id="srct0290">Nagalla, S., Chou, J.W., Willingham, M.C., Ruiz, J., Vaughn, J.P., Dubey, P., Lash, T.L., Hamilton-Dutoit, S.J., Bergh, J., Sotiriou, C., et&#x000a0;al. (2013). Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 14, R34.</mixed-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Nemkov</surname><given-names>T.</given-names></name><name><surname>D&#x02019;Alessandro</surname><given-names>A.</given-names></name><name><surname>Hansen</surname><given-names>K.C.</given-names></name></person-group><article-title>Three-minute method for amino acid analysis by UHPLC and high-resolution quadrupole orbitrap mass spectrometry</article-title><source>Amino Acids</source><volume>47</volume><year>2015</year><fpage>2345</fpage><lpage>2357</lpage><pub-id pub-id-type="pmid">26058356</pub-id></element-citation><mixed-citation id="srct0295">Nemkov, T., D&#x02019;Alessandro, A., and Hansen, K.C. (2015). Three-minute method for amino acid analysis by UHPLC and high-resolution quadrupole orbitrap mass spectrometry. Amino Acids 47, 2345-2357.</mixed-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>V.T.</given-names></name><name><surname>Barozzi</surname><given-names>I.</given-names></name><name><surname>Faronato</surname><given-names>M.</given-names></name><name><surname>Lombardo</surname><given-names>Y.</given-names></name><name><surname>Steel</surname><given-names>J.H.</given-names></name><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>Darbre</surname><given-names>P.</given-names></name><name><surname>Castellano</surname><given-names>L.</given-names></name><name><surname>Gy&#x00151;rffy</surname><given-names>B.</given-names></name><name><surname>Woodley</surname><given-names>L.</given-names></name></person-group><article-title>Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion</article-title><source>Nat. Commun.</source><volume>6</volume><year>2015</year><fpage>10044</fpage><pub-id pub-id-type="pmid">26610607</pub-id></element-citation><mixed-citation id="srct0300">Nguyen, V.T., Barozzi, I., Faronato, M., Lombardo, Y., Steel, J.H., Patel, N., Darbre, P., Castellano, L., Gy&#x00151;rffy, B., Woodley, L., et&#x000a0;al. (2015). Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nat. Commun. 6, 10044.</mixed-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>B.</given-names></name><name><surname>Chin</surname><given-names>S.F.</given-names></name><name><surname>Rueda</surname><given-names>O.M.</given-names></name><name><surname>Vollan</surname><given-names>H.K.</given-names></name><name><surname>Provenzano</surname><given-names>E.</given-names></name><name><surname>Bardwell</surname><given-names>H.A.</given-names></name><name><surname>Pugh</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>L.</given-names></name><name><surname>Russell</surname><given-names>R.</given-names></name><name><surname>Sammut</surname><given-names>S.J.</given-names></name></person-group><article-title>The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes</article-title><source>Nat. Commun.</source><volume>7</volume><year>2016</year><fpage>11479</fpage><pub-id pub-id-type="pmid">27161491</pub-id></element-citation><mixed-citation id="srct0305">Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., et&#x000a0;al. (2016). The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479.</mixed-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Plaza-Menacho</surname><given-names>I.</given-names></name><name><surname>Morandi</surname><given-names>A.</given-names></name><name><surname>Robertson</surname><given-names>D.</given-names></name><name><surname>Pancholi</surname><given-names>S.</given-names></name><name><surname>Drury</surname><given-names>S.</given-names></name><name><surname>Dowsett</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>L.A.</given-names></name><name><surname>Isacke</surname><given-names>C.M.</given-names></name></person-group><article-title>Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance</article-title><source>Oncogene</source><volume>29</volume><year>2010</year><fpage>4648</fpage><lpage>4657</lpage><pub-id pub-id-type="pmid">20531297</pub-id></element-citation><mixed-citation id="srct0310">Plaza-Menacho, I., Morandi, A., Robertson, D., Pancholi, S., Drury, S., Dowsett, M., Martin, L.A., and Isacke, C.M. (2010). Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 29, 4648-4657.</mixed-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>R&#x000e8;me</surname><given-names>T.</given-names></name><name><surname>Hose</surname><given-names>D.</given-names></name><name><surname>Theillet</surname><given-names>C.</given-names></name><name><surname>Klein</surname><given-names>B.</given-names></name></person-group><article-title>Modeling risk stratification in human cancer</article-title><source>Bioinformatics</source><volume>29</volume><year>2013</year><fpage>1149</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">23493321</pub-id></element-citation><mixed-citation id="srct0315">Reme, T., Hose, D., Theillet, C., and Klein, B. (2013). Modeling risk stratification in human cancer. Bioinformatics 29, 1149-1157.</mixed-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Rodriguez-Bravo</surname><given-names>V.</given-names></name><name><surname>Carceles-Cordon</surname><given-names>M.</given-names></name><name><surname>Hoshida</surname><given-names>Y.</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C.</given-names></name><name><surname>Galsky</surname><given-names>M.D.</given-names></name><name><surname>Domingo-Domenech</surname><given-names>J.</given-names></name></person-group><article-title>The role of GATA2 in lethal prostate cancer aggressiveness</article-title><source>Nat. Rev. Urol.</source><volume>14</volume><year>2017</year><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">27872477</pub-id></element-citation><mixed-citation id="srct0320">Rodriguez-Bravo, V., Carceles-Cordon, M., Hoshida, Y., Cordon-Cardo, C., Galsky, M.D., and Domingo-Domenech, J. (2017). The role of GATA2 in lethal prostate cancer aggressiveness. Nat. Rev. Urol. 14, 38-48.</mixed-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>R.</given-names></name><name><surname>Finetti</surname><given-names>P.</given-names></name><name><surname>Cervera</surname><given-names>N.</given-names></name><name><surname>Lambaudie</surname><given-names>E.</given-names></name><name><surname>Esterni</surname><given-names>B.</given-names></name><name><surname>Mamessier</surname><given-names>E.</given-names></name><name><surname>Tallet</surname><given-names>A.</given-names></name><name><surname>Chabannon</surname><given-names>C.</given-names></name><name><surname>Extra</surname><given-names>J.M.</given-names></name><name><surname>Jacquemier</surname><given-names>J.</given-names></name></person-group><article-title>A gene expression signature identifies two prognostic subgroups of basal breast cancer</article-title><source>Breast Cancer Res. Treat.</source><volume>126</volume><year>2011</year><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">20490655</pub-id></element-citation><mixed-citation id="srct0325">Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., Tallet, A., Chabannon, C., Extra, J.M., Jacquemier, J., et&#x000a0;al. (2011). A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res. Treat. 126, 407-420.</mixed-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Coyaud</surname><given-names>E.</given-names></name><name><surname>Luna</surname><given-names>A.</given-names></name><name><surname>Sander</surname><given-names>C.</given-names></name><name><surname>Raught</surname><given-names>B.</given-names></name><name><surname>Asara</surname><given-names>J.M.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Muthuswamy</surname><given-names>S.K.</given-names></name></person-group><article-title>LLGL2 rescues nutrient stress by promoting leucine uptake in ER<sup>+</sup> breast cancer</article-title><source>Nature</source><volume>569</volume><year>2019</year><fpage>275</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">30996345</pub-id></element-citation><mixed-citation id="srct0330">Saito, Y., Li, L., Coyaud, E., Luna, A., Sander, C., Raught, B., Asara, J.M., Brown, M., and Muthuswamy, S.K. (2019). LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer. Nature 569, 275-279.</mixed-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>C.G.</given-names></name><name><surname>Ma</surname><given-names>C.X.</given-names></name><name><surname>Crowder</surname><given-names>R.J.</given-names></name><name><surname>Guintoli</surname><given-names>T.</given-names></name><name><surname>Phommaly</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Ellis</surname><given-names>M.J.</given-names></name></person-group><article-title>Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer</article-title><source>Breast Cancer Res.</source><volume>13</volume><year>2011</year><fpage>R21</fpage><pub-id pub-id-type="pmid">21362200</pub-id></element-citation><mixed-citation id="srct0335">Sanchez, C.G., Ma, C.X., Crowder, R.J., Guintoli, T., Phommaly, C., Gao, F., Lin, L., and Ellis, M.J. (2011). Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 13, R21.</mixed-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Shajahan-Haq</surname><given-names>A.N.</given-names></name><name><surname>Cook</surname><given-names>K.L.</given-names></name><name><surname>Schwartz-Roberts</surname><given-names>J.L.</given-names></name><name><surname>Eltayeb</surname><given-names>A.E.</given-names></name><name><surname>Demas</surname><given-names>D.M.</given-names></name><name><surname>Warri</surname><given-names>A.M.</given-names></name><name><surname>Facey</surname><given-names>C.O.</given-names></name><name><surname>Hilakivi-Clarke</surname><given-names>L.A.</given-names></name><name><surname>Clarke</surname><given-names>R.</given-names></name></person-group><article-title>MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer</article-title><source>Mol. Cancer</source><volume>13</volume><year>2014</year><fpage>239</fpage><pub-id pub-id-type="pmid">25339305</pub-id></element-citation><mixed-citation id="srct0340">Shajahan-Haq, A.N., Cook, K.L., Schwartz-Roberts, J.L., Eltayeb, A.E., Demas, D.M., Warri, A.M., Facey, C.O., Hilakivi-Clarke, L.A., and Clarke, R. (2014). MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol. Cancer 13, 239.</mixed-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C.S.</given-names></name><name><surname>Kehrl</surname><given-names>J.H.</given-names></name></person-group><article-title>TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy</article-title><source>Sci. Signal.</source><volume>3</volume><year>2010</year><fpage>ra42</fpage><pub-id pub-id-type="pmid">20501938</pub-id></element-citation><mixed-citation id="srct0345">Shi, C.S., and Kehrl, J.H. (2010). TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci. Signal. 3, ra42.</mixed-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Shinmura</surname><given-names>K.</given-names></name><name><surname>Kato</surname><given-names>H.</given-names></name><name><surname>Igarashi</surname><given-names>H.</given-names></name><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Nakamura</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>C.</given-names></name><name><surname>Kurachi</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Ogawa</surname><given-names>H.</given-names></name><name><surname>Tanahashi</surname><given-names>M.</given-names></name></person-group><article-title>CD44-SLC1A2 fusion transcripts in primary colorectal cancer</article-title><source>Pathol. Oncol. Res.</source><volume>21</volume><year>2015</year><fpage>759</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">25576211</pub-id></element-citation><mixed-citation id="srct0350">Shinmura, K., Kato, H., Igarashi, H., Inoue, Y., Nakamura, S., Du, C., Kurachi, K., Nakamura, T., Ogawa, H., Tanahashi, M., et&#x000a0;al. (2015). CD44-SLC1A2 fusion transcripts in primary colorectal cancer. Pathol. Oncol. Res. 21, 759-764.</mixed-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Sim&#x000f5;es</surname><given-names>B.M.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>C.S.</given-names></name><name><surname>Eyre</surname><given-names>R.</given-names></name><name><surname>Silva</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Sarmiento-Castro</surname><given-names>A.</given-names></name><name><surname>Alf&#x000e9;rez</surname><given-names>D.G.</given-names></name><name><surname>Spence</surname><given-names>K.</given-names></name><name><surname>Santiago-G&#x01f79;mez</surname><given-names>A.</given-names></name><name><surname>Chemi</surname><given-names>F.</given-names></name></person-group><article-title>Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity</article-title><source>Cell Rep</source><volume><italic>12</italic></volume><year>2015</year><fpage>1968</fpage><lpage>1977</lpage><pub-id pub-id-type="pmid">26387946</pub-id></element-citation><mixed-citation id="srct0355">Simoes, B.M., O&#x02019;Brien, C.S., Eyre, R., Silva, A., Yu, L., Sarmiento-Castro, A., Alferez, D.G., Spence, K., Santiago-G&#x01f79;mez, A., Chemi, F., et&#x000a0;al. (2015). Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. Cell Rep. 12, 1968-1977.</mixed-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C.</given-names></name><name><surname>Wirapati</surname><given-names>P.</given-names></name><name><surname>Loi</surname><given-names>S.</given-names></name><name><surname>Harris</surname><given-names>A.</given-names></name><name><surname>Fox</surname><given-names>S.</given-names></name><name><surname>Smeds</surname><given-names>J.</given-names></name><name><surname>Nordgren</surname><given-names>H.</given-names></name><name><surname>Farmer</surname><given-names>P.</given-names></name><name><surname>Praz</surname><given-names>V.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name></person-group><article-title>Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis</article-title><source>J.&#x000a0;Natl. Cancer Inst.</source><volume>98</volume><year>2006</year><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">16478745</pub-id></element-citation><mixed-citation id="srct0360">Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et&#x000a0;al. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98, 262-272.</mixed-citation></ref><ref id="bib65"><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Tamayo</surname><given-names>P.</given-names></name><name><surname>Mootha</surname><given-names>V.K.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Ebert</surname><given-names>B.L.</given-names></name><name><surname>Gillette</surname><given-names>M.A.</given-names></name><name><surname>Paulovich</surname><given-names>A.</given-names></name><name><surname>Pomeroy</surname><given-names>S.L.</given-names></name><name><surname>Golub</surname><given-names>T.R.</given-names></name><name><surname>Lander</surname><given-names>E.S.</given-names></name><name><surname>Mesirov</surname><given-names>J.P.</given-names></name></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>102</volume><year>2005</year><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmid">16199517</pub-id></element-citation><mixed-citation id="srct0365">Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550.</mixed-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>L.B.</given-names></name><name><surname>Gui</surname><given-names>D.Y.</given-names></name><name><surname>Hosios</surname><given-names>A.M.</given-names></name><name><surname>Bush</surname><given-names>L.N.</given-names></name><name><surname>Freinkman</surname><given-names>E.</given-names></name><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells</article-title><source>Cell</source><volume>162</volume><year>2015</year><fpage>552</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">26232225</pub-id></element-citation><mixed-citation id="srct0370">Sullivan, L.B., Gui, D.Y., Hosios, A.M., Bush, L.N., Freinkman, E., and Vander Heiden, M.G. (2015). Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells. Cell 162, 552-563.</mixed-citation></ref><ref id="bib67"><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>L.B.</given-names></name><name><surname>Luengo</surname><given-names>A.</given-names></name><name><surname>Danai</surname><given-names>L.V.</given-names></name><name><surname>Bush</surname><given-names>L.N.</given-names></name><name><surname>Diehl</surname><given-names>F.F.</given-names></name><name><surname>Hosios</surname><given-names>A.M.</given-names></name><name><surname>Lau</surname><given-names>A.N.</given-names></name><name><surname>Elmiligy</surname><given-names>S.</given-names></name><name><surname>Malstrom</surname><given-names>S.</given-names></name><name><surname>Lewis</surname><given-names>C.A.</given-names></name><name><surname>Vander Heiden</surname><given-names>M.G.</given-names></name></person-group><article-title>Aspartate is an endogenous metabolic limitation for tumour growth</article-title><source>Nat. Cell Biol.</source><volume>20</volume><year>2018</year><fpage>782</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">29941931</pub-id></element-citation><mixed-citation id="srct0375">Sullivan, L.B., Luengo, A., Danai, L.V., Bush, L.N., Diehl, F.F., Hosios, A.M., Lau, A.N., Elmiligy, S., Malstrom, S., Lewis, C.A., and Vander Heiden, M.G. (2018). Aspartate is an endogenous metabolic limitation for tumour growth. Nat. Cell Biol. 20, 782-788.</mixed-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Symmans</surname><given-names>W.F.</given-names></name><name><surname>Hatzis</surname><given-names>C.</given-names></name><name><surname>Sotiriou</surname><given-names>C.</given-names></name><name><surname>Andre</surname><given-names>F.</given-names></name><name><surname>Peintinger</surname><given-names>F.</given-names></name><name><surname>Regitnig</surname><given-names>P.</given-names></name><name><surname>Daxenbichler</surname><given-names>G.</given-names></name><name><surname>Desmedt</surname><given-names>C.</given-names></name><name><surname>Domont</surname><given-names>J.</given-names></name><name><surname>Marth</surname><given-names>C.</given-names></name></person-group><article-title>Genomic index of sensitivity to endocrine therapy for breast cancer</article-title><source>J.&#x000a0;Clin. Oncol.</source><volume>28</volume><year>2010</year><fpage>4111</fpage><lpage>4119</lpage><pub-id pub-id-type="pmid">20697068</pub-id></element-citation><mixed-citation id="srct0380">Symmans, W.F., Hatzis, C., Sotiriou, C., Andre, F., Peintinger, F., Regitnig, P., Daxenbichler, G., Desmedt, C., Domont, J., Marth, C., et&#x000a0;al. (2010). Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol. 28, 4111-4119.</mixed-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>N.T.</given-names></name><name><surname>Ramnarayanan</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Oh</surname><given-names>H.K.</given-names></name><name><surname>Leong</surname><given-names>S.H.</given-names></name><name><surname>Lim</surname><given-names>S.S.</given-names></name><name><surname>Tan</surname><given-names>I.B.</given-names></name><name><surname>Ooi</surname><given-names>C.H.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>CD44-SLC1A2 gene fusions in gastric cancer</article-title><source>Sci. Transl. Med.</source><volume>3</volume><year>2011</year><fpage>77ra30</fpage></element-citation><mixed-citation id="srct0385">Tao, J., Deng, N.T., Ramnarayanan, K., Huang, B., Oh, H.K., Leong, S.H., Lim, S.S., Tan, I.B., Ooi, C.H., Wu, J., et&#x000a0;al. (2011). CD44-SLC1A2 gene fusions in gastric cancer. Sci. Transl. Med. 3, 77ra30.</mixed-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>S.J.</given-names></name><name><surname>Rodriguez-Bravo</surname><given-names>V.</given-names></name><name><surname>Quinn</surname><given-names>S.A.</given-names></name><name><surname>Rodriguez-Barrueco</surname><given-names>R.</given-names></name><name><surname>Lujambio</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>E.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>de la Iglesia-Vicente</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name><name><surname>Readhead</surname><given-names>B.</given-names></name></person-group><article-title>A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer</article-title><source>Cancer Cell</source><volume>27</volume><year>2015</year><fpage>223</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">25670080</pub-id></element-citation><mixed-citation id="srct0390">Vidal, S.J., Rodriguez-Bravo, V., Quinn, S.A., Rodriguez-Barrueco, R., Lujambio, A., Williams, E., Sun, X., de la Iglesia-Vicente, J., Lee, A., Readhead, B., et&#x000a0;al. (2015). A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 27, 223-239.</mixed-citation></ref><ref id="bib71"><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Klijn</surname><given-names>J.G.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sieuwerts</surname><given-names>A.M.</given-names></name><name><surname>Look</surname><given-names>M.P.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Talantov</surname><given-names>D.</given-names></name><name><surname>Timmermans</surname><given-names>M.</given-names></name><name><surname>Meijer-van Gelder</surname><given-names>M.E.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer</article-title><source>Lancet</source><volume>365</volume><year>2005</year><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">15721472</pub-id></element-citation><mixed-citation id="srct0395">Wang, Y., Klijn, J.G., Zhang, Y., Sieuwerts, A.M., Look, M.P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M.E., Yu, J., et&#x000a0;al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679.</mixed-citation></ref><ref id="bib72"><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Ngeow</surname><given-names>J.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name></person-group><article-title>GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer</article-title><source>Hum. Mol. Genet.</source><volume>21</volume><year>2012</year><fpage>569</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">22021428</pub-id></element-citation><mixed-citation id="srct0400">Wang, Y., He, X., Ngeow, J., and Eng, C. (2012). GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum. Mol. Genet. 21, 569-576.</mixed-citation></ref><ref id="bib73"><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Zhuang</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells</article-title><source>Gastroenterology</source><volume>145</volume><year>2013</year><fpage>1133</fpage><lpage>1143.e12</lpage><pub-id pub-id-type="pmid">23916944</pub-id></element-citation><mixed-citation id="srct0405">Wang, P., Zhang, J., Zhang, L., Zhu, Z., Fan, J., Chen, L., Zhuang, L., Luo, J., Chen, H., Liu, L., et&#x000a0;al. (2013). MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 145, 1133-1143.e12.</mixed-citation></ref><ref id="bib74"><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.A.</given-names></name><name><surname>Stires</surname><given-names>H.</given-names></name><name><surname>Belden</surname><given-names>W.J.</given-names></name><name><surname>Roepke</surname><given-names>T.A.</given-names></name></person-group><article-title>The Arcuate Estrogen-Regulated Transcriptome: Estrogen Response Element-Dependent and -Independent Signaling of ER&#x003b1; in Female Mice</article-title><source>Endocrinology</source><volume>158</volume><year>2017</year><fpage>612</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">28359086</pub-id></element-citation><mixed-citation id="srct0410">Yang, J.A., Stires, H., Belden, W.J., and Roepke, T.A. (2017). The Arcuate Estrogen-Regulated Transcriptome: Estrogen Response Element-Dependent and -Independent Signaling of ER&#x003b1; in Female Mice. Endocrinology 158, 612-626.</mixed-citation></ref><ref id="bib75"><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Yoshii</surname><given-names>S.R.</given-names></name><name><surname>Mizushima</surname><given-names>N.</given-names></name></person-group><article-title>Monitoring and Measuring Autophagy</article-title><source>Int. J. Mol. Sci.</source><volume>18</volume><year>2017</year><fpage>E1865</fpage><pub-id pub-id-type="pmid">28846632</pub-id></element-citation><mixed-citation id="srct0415">Yoshii, S.R., and Mizushima, N. (2017). Monitoring and Measuring Autophagy. Int. J. Mol. Sci. 18, E1865.</mixed-citation></ref><ref id="bib76"><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>M.S.</given-names></name><name><surname>Thamminana</surname><given-names>S.</given-names></name><name><surname>Shahryari</surname><given-names>V.</given-names></name><name><surname>Chiyomaru</surname><given-names>T.</given-names></name><name><surname>Deng</surname><given-names>G.</given-names></name><name><surname>Saini</surname><given-names>S.</given-names></name><name><surname>Majid</surname><given-names>S.</given-names></name><name><surname>Fukuhara</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>I.</given-names></name><name><surname>Arora</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e50203</fpage><pub-id pub-id-type="pmid">23189187</pub-id></element-citation><mixed-citation id="srct0420">Zaman, M.S., Thamminana, S., Shahryari, V., Chiyomaru, T., Deng, G., Saini, S., Majid, S., Fukuhara, S., Chang, I., Arora, S., et&#x000a0;al. (2012). Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One 7, e50203.</mixed-citation></ref><ref id="bib77"><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sieuwerts</surname><given-names>A.M.</given-names></name><name><surname>McGreevy</surname><given-names>M.</given-names></name><name><surname>Casey</surname><given-names>G.</given-names></name><name><surname>Cufer</surname><given-names>T.</given-names></name><name><surname>Paradiso</surname><given-names>A.</given-names></name><name><surname>Harbeck</surname><given-names>N.</given-names></name><name><surname>Span</surname><given-names>P.N.</given-names></name><name><surname>Hicks</surname><given-names>D.G.</given-names></name><name><surname>Crowe</surname><given-names>J.</given-names></name></person-group><article-title>The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy</article-title><source>Breast Cancer Res. Treat.</source><volume>116</volume><year>2009</year><fpage>303</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">18821012</pub-id></element-citation><mixed-citation id="srct0425">Zhang, Y., Sieuwerts, A.M., McGreevy, M., Casey, G., Cufer, T., Paradiso, A., Harbeck, N., Span, P.N., Hicks, D.G., Crowe, J., et&#x000a0;al. (2009). The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res. Treat. 116, 303-309.</mixed-citation></ref><ref id="bib78"><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Hao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Xi</surname><given-names>J.J.</given-names></name></person-group><article-title>Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis</article-title><source>Nat. Commun.</source><volume>2</volume><year>2011</year><fpage>554</fpage><pub-id pub-id-type="pmid">22109528</pub-id></element-citation><mixed-citation id="srct0430">Zhang, H., Hao, Y., Yang, J., Zhou, Y., Li, J., Yin, S., Sun, C., Ma, M., Huang, Y., and Xi, J.J. (2011). Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat. Commun. 2, 554.</mixed-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental Information</title><p id="p0300"><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Figures S1&#x02013;S7 and Table S3</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Table S1. Genes and miRNAs Differently Regulated in LTED Cell Derivatives When Compared to Parental MCF7 (Either in the Presence or Absence of Estrogen), Related to Figure&#x000a0;1</title></caption><media xlink:href="mmc2.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc3"><caption><title>Table S2. Gene Set Enrichment Analysis (GSEA) Relative to the Gene Expression Data of MCF7 (Either in the Presence or Absence of Estrogen), Related to Figure&#x000a0;1</title></caption><media xlink:href="mmc3.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc4"><caption><title>Document S2. Article plus Supplemental Information</title></caption><media xlink:href="mmc4.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>The work of A.M. was funded by <funding-source id="gs1">Fondazione Umberto Veronesi</funding-source>, <funding-source id="gs2">Associazione Italiana Ricerca sul Cancro</funding-source> (AIRC), and <funding-source id="gs3">Fondazione Cassa di Risparmio di Firenze</funding-source> (grant 19515 to P.C. and A.M.), and an <funding-source id="gs4">AIRC</funding-source> grant (8797) to P.C. M.B. is an <funding-source id="gs5">AIRC</funding-source> fellow. L.-A.M. is supported by <funding-source id="gs6">Breast Cancer Now</funding-source>, working in partnership with <funding-source id="gs7">Walk the Walk</funding-source>. M.M. is supported by <funding-source id="gs8">FWO</funding-source> (G0D1717N) and holds an <funding-source id="gs9">ERC</funding-source> consolidator grant (773208). We thank Prof. Massimo Negrini (University of Ferrara) and the facility of the Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA) for performing the miRNA and gene expression analyses, Angela Subbiani for helping with cell culturing, and Prof. Clare M. Isacke (The Institute of Cancer Research) for critical reading of the manuscript.</p><sec id="sec5"><title>Author Contributions</title><p id="p0285">The authors contributed to this work in different capacities, described as follows. M.B. performed cell-based and biochemistry experiments, study design, data acquisition, analysis, and interpretation; N.L. performed cell-based and biochemistry experiments, Seahorse and metabolic analysis, and participated in the interpretation of the data; L.I. performed Seahorse and metabolic analysis and participated in the interpretation of the data; M.R., Q.G., and M.F. performed gene expression, clinical data, and bioinformatic analyses; S.L. performed HPLC analysis and amino acid quantification; S.R. performed the cell-based experiments; M.P. performed the GC-MS analysis; F.B. performed the xenograft mouse model; B.M.S. and E.M. generated and performed the experiments on the patient-derived xenografts; F.C., F.V., and M.M. designed and performed the LC-MS analysis and data interpretation; L.-A.M. generated the LTED cell lines; G.C. and E.G. developed the methodology, provided administrative and technical support, interpreted the data; P.C. performed the data analysis and interpretation and revised the manuscript; A.M. conceived, designed, and supervised the study; performed the cell-based and metabolic experiments; analyzed and interpreted the data; and wrote the manuscript. All of the authors reviewed the prepared manuscript.</p></sec><sec id="sec6"><title>Declaration of Interests</title><p id="p0290">L.-A.M. receives academic funding from Radius Pharma, PUMA Biotechnology, and Pfizer. The other authors declare no competing interests.</p></sec></ack><fn-group><fn id="app1" fn-type="supplementary-material"><p id="p0295">Supplemental Information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.celrep.2019.06.010" id="intref0455">https://doi.org/10.1016/j.celrep.2019.06.010</ext-link>.</p></fn></fn-group></back></article>